

ASCIA 2016 CONFERENCE

27th Annual Conference of the Australasian
Society of Clinical Immunology and Allergy

GOLD COAST CONVENTION CENTRE QUEENSLAND, AUSTRALIA

14-17 SEPTEMBER 2016

PROGRAM BOOK

www.ascia2016.com

ascia

australasian society of clinical immunology and allergy

www.allergy.org.au

ASCIA is the peak professional body of clinical immunology and allergy specialists in Australia and New Zealand. ASCIA is a member society of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) and the World Allergy Organisation (WAO)

Sponsors

ASCIA gratefully acknowledges the generous support of the following sponsors:

Diamond Sponsors

CSL Behring



Platinum Sponsors



GRIFOLS



Gold Sponsors



Sponsors and exhibitors

- Abacus ALS
- Abbott
- Allergend
- Allergy & Anaphylaxis Australia
- Allergy New Zealand
- AusEE
- AMSL
- Autoimmune Resource & Research Ctr
- Bayer
- Centre for Food & Allergy Research
- CSL Behring
- Ego Pharmaceuticals
- ENT Technologies
- Grifols
- GSK
- HAE Australasia
- IDFA
- IDFNZ
- MEDA Pharmaceuticals
- MYLAN - Alphapharm
- National Asthma Council
- National Blood Authority
- Neilmed
- Nestlé Health Science
- Nestlé Nutrition
- Novartis
- Nutricia Advanced Medical Nutrition
- Danone Nutricia Early Life Nutrition
- Octapharma
- Seqirus
- Shire Australia
- Stallergenes Greer
- TAMS
- Western Allergy

Note: The ASCIA 2016 conference program is not influenced by its sponsors or exhibitors

Welcome

Contents

Sponsors and Exhibitors	1
Welcome	2
Information (A-Z)	3
Program Summary	5
CFAR Food and Allergy Symposium Program (Tuesday)	6
Conference Day 1 Program (Wednesday)	7
Conference Day 2 Program (Thursday)	8
Conference Day 3 Program (Friday)	9
Nurse and Dietitian Updates Program (Friday)	10
Postgraduate Immunology Course Program (Saturday)	12
International Speakers	13
Basten Orator	15
Speakers and Chairs Index (A-Z)	16
Abstract Author Index	19
ASCIA 2017	26
Exhibition Floorplan	27
Exhibitors	28
Sponsor and Exhibitor Directory	29

On behalf of the Australasian Society of Clinical Immunology and Allergy (ASCIA), it is our pleasure to welcome you to the ASCIA 2016 Annual Conference.

The main aim of ASCIA annual conferences is to provide an international standard of continuing professional development and opportunities to update knowledge for ASCIA members and other health professionals working in the areas of allergy and clinical immunology.

Presentations by international and local speakers cover a wide range of topics in the areas of allergic diseases, immunodeficiencies and other immune diseases.

The conference includes presentations from the following international speakers:

- Professor Abul Abbas
- Professor Marcus Maurer
- Dr Michael Perkin
- Dr Sergio Rosenzweig
- Professor Hugh Sampson
- Dr Glenis Scadding

There are also 62 speakers/chairs from Australasia, 48 poster/clinical grand rounds presenters and more than 500 delegates participating in this conference.

The ASCIA 2016 conference is being held in conjunction with the following meetings:

- **CFAR Symposium 2016** hosted by the Centre for Food and Allergy Research (CFAR) on Tuesday 13 September
- **ASCIA 2016 Nurse and Dietitian Updates** on Friday 16 September, run in parallel with conference sessions.
- **ASCIA 2016 Postgraduate Immunology Course** on Saturday 17 September

We trust that you will also take the opportunity to enjoy your visit to the Gold Coast whilst participating in the conference.

Dr Susan Perel

Dr Melanie Wong

Chair, ASCIA 2016 Conference Committee

ASCIA President

ASCIA 2016 Conference Committee:

Dr Susan Perel, A/Prof Jane Peake, Dr David Gillis

ASCIA 2016 Nurse and Dietitian Update Coordinators:

Kathy Beck, Anna Sullivan

Information (A-Z)

Abstracts

A total of 95 abstracts have been accepted for:

- ASCIA 2016 posters (displayed from Wednesday 14 to Friday 16 September 2016)
- ASCIA 2016 clinical grand rounds oral presentations on Friday 16 September 2016

All accepted abstracts are published in the online Internal Medicine Journal and these can be accessed on the ASCIA website: www.allergy.org.au/conferences/ascia-annual-conference/published-abstracts-ascia

Attendance Certificates

A certificate of attendance is provided to each delegate and is included in the registration envelope, together with a receipt for the registration payment.

Awards and Travel Scholarships

A limited number of travel scholarships of \$500 each are awarded (during the conference) to advanced trainees who reside outside of the region and have submitted an abstract for a poster and/or clinical grand round presentation.

Awards of \$1,000 each for selected posters and clinical grand round presentations will be presented at the end of the conference. After the conference these are listed on the ASCIA website:

www.allergy.org.au/health-professionals/awards-grants/ascia-award-grant-scholarship-recipients

Disclaimers

In the event of industrial disruption or a natural disaster the meeting organisers cannot be held responsible for any losses incurred by delegates.

The program is correct at the time of printing; however, the organisers reserve the right to alter the program if necessary.

Dress Code

The dress code is smart casual throughout the conference and cocktail for the Gala Dinner.

Exhibition

The exhibition for the ASCIA 2016 conference will run for 3 days, from Wednesday 14 to Friday 16 September 2016 and all lunches and tea breaks will be served in the exhibition area.

There will not be any exhibition on the Tuesday or Saturday.

Delegates are encouraged to visit the ASCIA 2016 exhibition stands throughout the conference.

Registration

Registration is available online at www.ascia2016.com

Special rates are available for ASCIA members, medical students and delegates from developing countries.

Secretariat - registration, abstract submission, website



Email registration@ascia2016.com

Secretariat - sponsorship, exhibition, program



Email: education@allergy.org.au or admin@allergy.org.au

Smoke Free Policy

It is the policy that the ASCIA 2016 conference is smoke-free, including all related social functions.

Social Program

ASCIA 2016 Welcome Function

Wednesday 14 September, 17.30-18.30

Hall Foyers 3 and 4, Gold Coast Convention and Exhibition Centre

HAE Educational Dinner Meeting – supported by Shire

Wednesday 14 September, 18.30-21.30

Central Room A, Gold Coast Convention and Exhibition Centre

ASCIA 2016 Gala Dinner

Thursday 15 September, 18.30-22.30

SkyPoint Level 78 - Q1 Resort, 9 Hamilton Avenue, Surfers Paradise, Gold Coast

This venue features spectacular views ranging from the famous coastline to the hinterland and beyond.

ASCIA 2016 Closing Function (including award presentations)

Friday 16 September, 17.00-18.00

Hall Foyers 3 and 4, Gold Coast Convention and Exhibition Centre

ASCIA 2016 Trainees and Consultants Dinner Meeting – supported by CSL Behring

Meeting Room 9, Friday 16 September, 18.00-21.30

Gold Coast Convention and Exhibition Centre

Special Requirements

Please provide details of any special diet, special needs or disability assistance required when you register.

Travel

Regular flights to the Gold Coast (Coolangatta) and Brisbane airports are available from capital cities throughout Australia and New Zealand.

Information about the train from Brisbane Airport to Nerang on the Gold Coast is available at:

<https://airtrain.com.au/gold-coast-connect>

<https://www.airtrain.com.au/checkout/journey-information>

Information about the light rail service that operates from a range of stops from Southport to the Gold Coast Convention and Exhibition Centre is available at:

<http://ridetheg.com.au/>



Program Summary

Tuesday 13 September	Wednesday 14 September	Thursday 15 September	Friday 16 September	Saturday 17 September	Saturday 18 September
CFAR Symposium	Conference Day 1	Conference Day 2	Conference Day 3	Nurse and Dietitian Updates Hall F	Postgraduate Immunology Course
Registration	Registration Breakfast Session: JSAC Forum Supervisors and Trainees	Breakfast Session: Immunotherapy Symposium	Breakfast Session: Difficult PID cases	Concurrent Breakfast Sessions: ASCIA Nurse and Dietitian committee meetings	Registration
EAT study Hot publications in food allergy research	Allergy Plenary	Immunodeficiency Plenary	Autoimmunity Plenary	Concurrent Sessions: Dermatology Workshop Food Allergy Training and Overview of Resources	Introduction to the Immune System Innate Immunity
Morning Tea					
Infant Feeding Summit National Allergy Strategy food allergy initiatives Priorities for food allergy research	Food Allergy Symposium	Clinical Management Symposium (with international experts)	Allergic Rhinitis Symposium	Combined Session: Food Allergy through the Lifespan - Infant Feeding and Early School Age	Antigen Presentation, T Cell Activation and Co-stimulation CF4 T Cell Subsets, Cytokines
Lunch					
Screening for food allergy More hot publications in food allergy research Treatment trials for peanut and other allergies	Allergy and Skin Symposium	Basten Oration ASCIA AGM including National Allergy Strategy Update	Clinical Grand Rounds	Combined Session: Food Allergy through the Lifespan – Adolescents What can we learn from times when food allergy goes wrong?	B Cells and Antibodies T Cell Regulation and Tolerance I – Central and Peripheral Tolerance
Afternoon Tea					
Permissive labelling – Are we ready for it? Defining priorities in food allergy research and knowledge translation - Where to next?	Poster Rounds - Food and Environmental Allergy	Poster Rounds – Drug Allergy, Primary Immunodeficiency, Autoimmunity, other Immunology	Quiz	Concurrent sessions: PID and SCIG Update Food Allergen Challenges and Food Allergy Research Update	T Cell Regulation and Tolerance II – Regulatory T Cells, Failure of Tolerance Tumour Immunology
	Welcome Function – Convention Centre	Gala Dinner - SkyPoint Level 78, Q1 Resort	Closing Function – Convention Centre	Closing Function – Convention Centre	

CFAR Food and Allergy Symposium Program

Tuesday 13 September 2016

Arena 1A, Gold Coast Convention and Exhibition Centre

Hosted by:



07.30-09.00	Registration	
09.00-09.15	Welcome and introductions Prof Katie Allen - Director, NHMRC Centre for Food & Allergy Research (CFAR)	
09.15-10.15	Keynote presentation: EAT study Will the change in infant feeding guidelines prevent food allergy?	Dr Michael Perkin
10.15-11.00	Hot publications in food allergy research (micro presentations)	
11.00-11.30	Morning Tea	
11.30-11.45	Infant feeding Summit Consensus - what we have achieved	Dr Merryn Netting
11.45-12.00	National Allergy Strategy food allergy initiatives	A/Prof Richard Loh
12.00-12.30	Panel discussion: National priorities for food allergy research Chair: A/Prof Richard Loh Panel: Dr Melanie Wong, Dr Brynn Wainstein, Dr Ray Mullins, Prof Katie Allen, Maria Said	
12.30-13.30	Lunch	
13.30-13.40	Implementing early introduction of peanut in the Barwon region	A/Prof Peter Vuillermin
13.40-14.15	Panel discussion: Screening for food allergy: To screen or not to screen? Implications of LEAP, EAT, STEP, STAR, HEAP and BEAT studies What is the rest of the world doing? Chair: Prof Dianne Campbell Panel: Dr Michael Perkin, Prof Hugh Sampson, Prof Mimi Tang, A/Prof Richard Loh, Dr Debra Palmer	
14.15-14.45	More hot publications in food allergy research (micro presentations)	
14.45-15.30	Treatment trials for peanut allergy and other food allergies EPIT (Epicutaneous immunotherapy) PPOIT (Probiotic and peanut oral immunotherapy) Q&A	Prof Hugh Sampson Prof Mimi Tang
15.30-16.00	Afternoon Tea	
16.00-16.10	Permissive labelling - Are we ready for it?	Dr Giovanni Zurzolo
16.10-16.30	Panel discussion: Permissive labelling - Are we ready for it? Chair: Prof Katie Allen Panel: Dr Michael Perkin, Maria Said, Prof Dianne Campbell, A/Prof Richard Loh, Dr Giovanni Zurzolo	
16.30-17.15	Closing presentation and discussion: Defining priorities in food allergy research and knowledge translation - Where to next?	Prof Katie Allen

Conference Day 1 Program

Wednesday 14 September 2016

07.30-09.00	Registration – Hall Foyer 3	
07.45-08.45	BREAKFAST SESSION: JSAC forum for supervisors and trainees – Hall 4 Chair: Dr Melanie Wong Breakfast will be served in Hall 4 Foyer from 07.30-08.00	
08.50-09.00	Welcome from ASCIA President and ASCIA 2016 Chair Dr Melanie Wong, Dr Susan Perel	
09.00–10.30	ALLERGY PLENARY – Hall 4 Chairs: Dr Melanie Wong, Dr Susan Perel	
09.00-09.45	The “second wave” of the allergy epidemic (atopic dermatitis and food allergy): Can we reverse it?	Prof Hugh Sampson
09.45-10.30	Pathogenesis of chronic urticaria	Prof Marcus Maurer
10.30-11.00	Morning Tea – Hall 3	
11.00-12.30	FOOD ALLERGY SYMPOSIUM – Hall 4 Chairs: A/Prof Jane Peake, Prof Dianne Campbell	
11.00-11.40	What should we EAT?	Dr Michael Perkin
11.40-12.10	Food allergy immunotherapies on the horizon	Prof Hugh Sampson
12.10-12.30	HealthNuts update	Prof Katie Allen
12.30-13.30	Lunch – Hall 3	
13.30-15.00	ALLERGY AND SKIN SYMPOSIUM – Hall 4 Chairs: Dr Paul Campbell, Dr David Heyworth-Smith	
13.30-14.00	Mastocytosis and mast cell biology	Prof Marcus Maurer
14.00-14.30	Drug reactions, the syphilis of the 21st century	Dr Jim Muir
14.30-15.00	Updates in allergic contact dermatitis	A/Prof Greg Siller
15.00-15.30	Afternoon Tea – Hall 3	
15.00-15.30	ASCIA Education committee meeting – Hall 3 meeting zone	
15.30-17.30	POSTER ROUNDS - Hall 3 FOOD AND ENVIRONMENTAL ALLERGY Chairs: A/Prof Richard Loh, Dr Brynn Wainstein	
15.30-16.00	Poster viewing – Poster authors should stand by their poster during this session	
16.00-17.30	Poster presentations – This session includes 16 selected oral poster presentations	
17.30-18.30	WELCOME FUNCTION – Hall Foyers 3 and 4	Gold Coast Convention and Exhibition Centre

ASCIA 2016 Conference Day 2 Program

Thursday 15 September 2016

07.30-09.00	Registration – Hall Foyer 3	
07.45-08.45	BREAKFAST SESSION: IMMUNOTHERAPY SYMPOSIUM – Hall 4 Chair: Prof Connie Katelaris Allergen Immunotherapy – past, present and future Breakfast will be served in Hall 4 Foyer from 07.30-08.00 <i>This breakfast session is supported by Seqirus, a CSL company</i>	Dr Glenis Scadding
09.00-10.30	IMMUNODEFICIENCY PLENARY – Hall 4 Chairs: A/Prof Jane Peake, Dr Paul Gray	
09.00-09.40	CVID and the legend of IKAROS	Dr Sergio Rosenzweig
09.40-10.05	Defects in lymphocyte development and function in primary immunodeficiencies	Prof Stuart Tangye
10.05-10.30	Two newly discovered CVID genes	A/Prof Rohan Ameratunga
10.30-11.00	Morning Tea – Hall 3	
11.00-12.30	CLINICAL MANAGEMENT SYMPOSIUM – Hall 4 Chairs: Dr David Gillis, Prof Connie Katelaris	
11.00-11.30	How I approach the diagnosis of a patient with suspected immune deficiency in 2016: genetics first versus genetics last?	Dr Sergio Rosenzweig
11.30-12.00	How I manage patients with multiple food allergy	Prof Hugh Sampson
12.00-12.30	How I manage patients with angioedema	Prof Marcus Maurer
12.30-13.30	Lunch – Hall 3	
12.30-13.30	ASCIA Drug Allergy Working Party meeting – Hall 3 meeting zone	
13.30-14.45	BASTEN ORATION – Hall 4 Chairs: Prof Tony Basten AO, Dr Pat Hogan Early advances in IgE antibody and eosinophil function	Dr Graham Solley
14.15-15.00	ASCIA ANNUAL GENERAL MEETING – Hall 4 Chair: Dr Melanie Wong including National Allergy Strategy Update	
15.00-15.30	Afternoon Tea – Hall 3	
15.30-17.30	POSTER ROUNDS - Hall 3 DRUG ALLERGY, PRIMARY IMMUNODEFICIENCY, AUTOIMMUNITY, OTHER IMMUNOLOGY Chairs: Dr Kate Nicholls, Dr David Gillis	
15.30-16.00	Poster viewing - Poster authors should stand by their poster during this session	
16.00-17.30	Poster presentations - This session includes 16 selected oral poster presentations	
18.30-22.30	GALA DINNER - SkyPoint Level 78 - Q1 Resort, 9 Hamilton Avenue, Surfers Paradise, Gold Coast	

Conference Day 3 Program

Friday 16 September 2016

07.30-09.00	Registration – Hall Foyer 3	
07.45-08.45	BREAKFAST SESSION: DIFFICULT PID CASES – Hall 4 Expert panel – Dr Sergio Rosenzweig, Dr Melanie Wong, Dr Paul Gray Chair: A/Prof Jane Peake Breakfast will be served in Hall 4 Foyer from 07.30-08.00 <i>This breakfast session is supported by an unrestricted educational grant from CSL Behring</i>	
09.00–10.30	AUTOIMMUNITY PLENARY – Hall 4 Chairs: Dr Pat Hogan, Dr Karen Morwood	
09.00-09.30	Strategies for restoring tolerance in immunological diseases	Prof Abul Abbas
09.30-10.30	Autoimmunity debate Topic: B-cell depletion therapy has revolutionised the treatment of autoimmune disease The case for: The case against:	A/Prof Sean Riminton Dr Daman Langguth
10.30-11.00	Morning Tea – Hall 3	
11.00-12.30	ALLERGIC RHINITIS SYMPOSIUM – Hall 4 Chairs: Dr Carl Kennedy, Prof Pete Smith	
11.00-11.40	New developments in allergen immunotherapy	Dr Glenis Scadding
11.40-12.05	A multicentre cross-sectional grass pollen allergy survey; Regional differences in allergic sensitisation to grass pollen allergens	A/Prof Janet Davies
12.05-12.30	Oral allergy syndrome	Prof Connie Katelaris
12.30-13.30	Lunch – Hall 3	
13.30-15.30	CLINICAL GRAND ROUNDS – Hall 4 This session includes 16 selected oral presentations by advanced trainees Chairs: Dr William Smith, Dr Alberto Pinzon	
15.30-16.00	Afternoon Tea – Hall 3	
16.00-17.00	QUIZ – Hall 4 Chairs: Dr Anthony Smith, Dr Alberto Pinzon	
17.00-18.00	Closing Function – Hall Foyers 3 and 4, Gold Coast Convention and Exhibition Centre	

ASCIA 2016 Conference Day 3 Program

Nurse and Dietitian Updates Friday 16 September 2016

07.30-09.00	Registration – Hall Foyer 3	
07.45-08.45	CONCURRENT BREAKFAST SESSIONS: ASCIA NURSE AND DIETITIAN COMMITTEE MEETINGS	
	ASCIA NURSES COMMITTEE MEETING – Meeting room 9	Chair: Val Noble
	Including updates on ASCIA Nurse Special Interest Groups: Dermatology (Jan Belcher), Nurse Practitioner (Naomi Fenton), Paediatric Allergy (Val Noble), Research (Carolina Valerio).	
	ASCIA DIETITIANS COMMITTEE MEETING – Hall 3	Chair: Ingrid Roche
09.00–10.30	CONCURRENT SESSIONS: DERMATOLOGY, FOOD ALLERGY TRAINING AND RESOURCES	
09.00-10.30	DERMATOLOGY SYMPOSIUM – Meeting room 9	Chairs: Jan Belcher, Emily Casey
09.00-09.40	Eczema management from a Paediatric Eczema Nurse Practitioner's perspective	Liz Leins
09.40-10.20	Allergy and the skin from an Allergy Nursing perspective	Deryn Thompson
10.20-10.30	Discussion and questions	
09.00-10.30	FOOD ALLERGY TRAINING AND OVERVIEW OF RESOURCES – Hall 3	Chairs: Kathy Beck, Anna Majchrzak
09.00-10.10	Food allergy training	Ingrid Roche
10.10-10.30	Overview of food allergy resources	Sandra Vale
10.30-11.00	Morning Tea – Hall 3	
11.00-12.30	COMBINED SESSION: FOOD ALLERGY THROUGH THE LIFESPAN – INFANT FEEDING AND EARLY SCHOOL AGE – Hall 3	
	Chairs: Paula Brown, Jillian Dimock	
11.00-11.40	Infant feeding	Dr Merryn Netting, Dr Debra Palmer
11.40-12.10	Teaching young children about managing their food allergy	Dr Merryn Netting
12.10-12.30	Support and resources for families	Maria Said, Anna Richards
12.30-13.30	Lunch – Hall 3	
13.30-15.30	COMBINED SESSION: FOOD ALLERGY THROUGH THE LIFESPAN (CONTINUED) – ADOLESCENTS WHAT CAN WE LEARN FROM TIMES WHEN FOOD ALLERGY GOES WRONG? – Hall 3	
13.30-14.30	FOOD ALLERGY THROUGH THE LIFESPAN – ADOLESCENTS	Chairs: Dr Anne Swain, Wendy Stuart-Smith
13.30-13.45	An overview of food allergy in adolescents (SchoolNuts data)	Leone Thiele
13.45-14.00	Case studies	Kathy Beck
14.00-14.15	Transition	Anna Richards
14.15-14.30	Support and resources for adolescence and transition	Maria Said

Conference Day 3 Program

Nurse and Dietitian Updates (continued)

Friday 16 September 2016

14.30-15.30	WHAT CAN WE LEARN FROM TIMES WHEN FOOD ALLERGY GOES WRONG? – Hall 3	Chair: Anna Richards
14.30-14.50	The challenges of food allergy in the hospital environment	Ingrid Roche
14.50-15.10	Food recalls	Kathy Beck
15.10-15.30	Management and reporting after an adverse reaction to food	Maria Said
15.30-16.00	Afternoon Tea – Hall 3	
16.00-17.00	CONCURRENT SESSIONS: SCIg AND PID, FOOD CHALLENGES AND FOOD ALLERGY RESEARCH	
16.00-17.00	SCIG AND PID UPDATE – Meeting Room 9	Chair: Anna Sullivan
16.00-16.20	SCIg experience in Queensland	Anna Sullivan, Janine English
16.20-16.40	SCIg experience in New Zealand	Simone Stephens
16.40-17.00	IRT interest group discussion, including use of SCIg resources and overview of SCIg in Australia	
16.00-17.00	FOOD ALLERGEN CHALLENGES AND FOOD ALLERGY RESEARCH UPDATES – Hall 3	Chairs: Val Noble, Ingrid Roche
16.00-16.30	Food Allergen Challenges Update	Rebecca Sertori, Carolina Valerio
16.30-17.00	Food Allergy Research Update	Dr Debra Palmer
17.00-18.00	Closing Function – Hall Foyers 3 and 4, Gold Coast Convention and Exhibition Centre	

Postgraduate Immunology Course

Saturday 17 September 2016 Meeting Rooms 5-7

A SURVEY COURSE: UPDATE AND NEW CONCEPTS IN BASIC AND TRANSLATIONAL IMMUNOLOGY

Course Director: Prof Abul Abbas, University of California San Francisco

08.00–08.30	Registration
08.30–09.00	Introduction to the Immune System
09.00–10.00	Innate Immunity
10.30–10.30	Morning Tea
10.30–11.30	Antigen Presentation, T Cell Activation and Co-stimulation
11.30–12.30	CD4 T Cell Subsets, Cytokines
12.30–13.15	Lunch
13.15–14.00	B Cells and Antibodies
14.00–14.45	T Cell Regulation and Tolerance I. Central and Peripheral Tolerance
14.45–15.15	Afternoon Tea
15.15–16.15	T Cell Regulation and Tolerance II. Regulatory T Cells, Failure of Tolerance
16.15–17.00	Tumor Immunity
17.00	Meeting closed

International Keynote Speakers

Professor Abul K. Abbas MBBS

Professor and Chairman, Department of Pathology, University of California, San Francisco, USA



Professor Abbas received his MBBS in India, completed training in Pathology at Harvard and joined the faculty at Harvard Medical School and the Brigham and Women's Hospital, where he later became Professor of Pathology and Head of the Immunology Research Division. In 1999, after twenty years on the Harvard faculty, he moved to the University of California San Francisco (UCSF) as Professor and Chairman of the Department of Pathology.

His research interests are in Immunology, with a focus on the control of immune responses and the causes of autoimmunity. His laboratory has used experimental models to analyze the generation and maintenance of regulatory T cells. Professor Abbas has published over 200 peer-reviewed papers and invited reviews, and is the author of four widely read textbooks, two in Immunology and two in Pathology. He has taught Immunology at Harvard Medical School and UCSF, and has organized and conducted Immunology courses worldwide, including in Australia in 2011, 2013 and 2016, as part of the ASCIA Annual Conference.

Professor Abbas has received several honors, including election to the Institute of Medicine of the National Academy of Sciences, election as a Fellow of the American Academy of Arts and Sciences, and the Rous-Whipple Award and Robbins Educator Award of the American Society of Investigative Pathology. He has served as one of the founding Editors and Associate Editor of *Immunity*, Associate Editor and Section Editor for the *Journal of Immunology*, Associate Editor of *Cell*, Consulting Editor of the *Journal of Clinical Investigation*, founding Editor of the *Annual Review of Pathology: Mechanisms of Disease*, and Co-Chief Scientific Advisor of *Science Immunology*. From 2011 to 2013, he was the President of the Federation of Clinical Immunology Societies (FOCIS).

Professor Marcus Maurer MD

Professor of Dermatology and Allergy, Director of Research-Department of Dermatology and Allergy, and Associate Director of the Allergie-Centrum-Charité, Charité-Universitätsmedizin (University Hospital) Berlin, Germany



Professor Maurer trained in dermatology and allergology in Berlin and Mainz, and in experimental pathology at the Beth Israel Deaconess Hospital and Harvard Medical School in Boston from 1995 to 1998. He attained his board certification for dermatology in 2000 and allergology in 2003. His habilitation "Why do we have mast cells?" was undertaken at the University of Mainz in 2003.

Professor Maurer's research focuses on physiological and pathological functions of mast cells. He has made numerous important contributions to the understanding of the role of mast cells in the pathogenesis of chronic inflammatory disorders as well as in the protection from infections. His clinical emphasis is on urticaria, mastocytosis, angioedema, hereditary angioedema, pruritus, and auto-inflammatory syndromes. He is the head of the Specialty Clinics for these conditions as well as the Dermatological Allergology Laboratory at the Charité University Hospital in Berlin.

Lately, Professor Maurer's team has also followed translational approaches using human in vivo and ex vivo models to investigate the functions of human mast cells, mostly skin mast cells. These investigations have led, among others, to the development of the concept of autoallergy in chronic urticaria. This was critical for the clinical testing and develop of anti-IgE as a novel treatment option in chronic spontaneous urticaria, a treatment that was licensed for use in this disease in 2014. Professor Maurer's team has built national reference centres for the investigation and treatment of urticaria, mastocytosis, hereditary angioedema, angioedema and other mast cell-driven diseases, and more than 30 randomized controlled trials (phase I through IV) were performed by him and his team since 2011. He is the author of more than 380 publications in peer reviewed journals including *Nature* and the *New England Journal of Medicine*.

Professor Maurer's travel is supported by an unrestricted educational grant from Shire.

Dr Michael Perkin MBBS BSc MSc DCH MRCP MRCPC PhD

Senior Lecturer and Consultant in Paediatric Allergy, St George's Hospital, London, UK



Dr Perkin trained at St George's Hospital and then undertook clinical allergy training at St Mary's and Southampton Hospitals. He held a Wellcome Fellowship in Clinical Epidemiology under Professor David Strachan.

Dr Perkin's research interests are the epidemiology of allergic disease, the prevention of food allergy and the environmental contribution to the allergy epidemic. His PhD was on the relationships between atopy and the farming environment in children.

For the last eight years Dr Perkin ran the Enquiring About Tolerance (EAT) Study: Feasibility of an early allergenic food introduction regimen. The main components of the EAT study were jointly funded by the UK Food Standards Agency (FSA) and the Medical Research Council (MRC). The results of the EAT study were published in March 2016 in the *New England Journal of Medicine*: [www.jacionline.org/article/S0091-6749\(16\)00135-4/fulltext](http://www.jacionline.org/article/S0091-6749(16)00135-4/fulltext)

Dr Perkin's travel is supported by CFAR (Centre for Food and Allergy Research), an NHMRC Centre of Research Excellence.

Dr Sergio D. Rosenzweig MD PhD

Director of the Primary Immunodeficiency Clinic, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and Chief of the Immunology Service, Clinical Center, NIH, USA



Dr Rosenzweig is a pediatrician and immunologist with more than 20 years of experience in the field of clinical immunology and human immunology research. He did his training in Buenos Aires, Argentina and at the NIH, USA.

Since 2009 he has served at the NIH as Director of the Primary Immunodeficiency Clinic. Since 2013 he has also served at the NIH as Chief of the Immunology Service, Clinical Center.

His career is committed to the field of primary immunodeficiency and immune dysregulation diseases with a focus on patient oriented diagnosis, clinical care, treatment, education and research.

Dr Rosenzweig has more than 50 peer-reviewed

publications, is an active member of multiple scientific societies, including the Clinical Immunology Society (CIS), the European Society for Immunodeficiencies (ESID) and the Latin American Society for Immunodeficiencies (LASID). He also serves as an associated editor for the journals *Frontiers in Primary Immunodeficiencies* and *Frontiers in Pediatrics*.

Professor Hugh A. Sampson MD

Kurt Hirschhorn Professor of Pediatrics and Director of the Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, USA



Professor Sampson has nearly 35 years' experience in translational research focusing on food allergic disorders and basic immunologic mechanisms responsible for these disorders. He received his medical degree from the State University of New York at Buffalo School of Medicine. This was followed by a residency in Pediatrics at the Children's Memorial Hospital and a fellowship in Allergy and Immunology at Duke University Hospital.

Professor Sampson's research has been funded continuously by a number of grants from the National Institutes of Health (NIH) including being the Principal Investigator for the Consortium for Food Allergy Research. He was elected to membership in the Institute of Medicine of the National Academies in 2003 for his research accomplishments.

Professor Sampson has published over 450 articles, 88 book chapters and co-edited 7 books, primarily on clinical and immunopathogenic aspects of food allergic disorders. He is past chair of the Section on Allergy and Immunology of the American Academy of Pediatrics and the past president of the American Academy of Allergy, Asthma and Immunology (AAAAI). His presidential initiative during his tenure led to the NIAID Guidelines on the Diagnosis and Management of Food Allergy. He has served on the Editorial Board of 5 allergy Journals, including 20 years on the JACI Editorial Board. In November 2015 he stepped-down as Dean for Translational Biomedical Sciences at Mount Sinai to devote 40% of his time to DBV Technologies as their Chief Scientific Officer.

International Keynote Speakers

Dr Glenis K. Scadding MD FRCP

Honorary Consultant Physician in Allergy and Rhinology, Royal National Throat, Nose and Ear Hospital and Honorary Senior Lecturer in Clinical Immunology at the University College London School of Medicine Accredited in Clinical Immunology and Allergy



Dr Scadding was Secretary of the British Society for Allergy and Clinical Immunology (BSACI) from 2007 to 2009 and President from 2009 to 2012. In 2006, she won the BSACI William Frankland Award for outstanding contribution to clinical allergy in the UK, was Allergy UK Allergist of the Year in 2011 and was awarded prizes by BMA (Walter Jobson Horne for ENT research), EAACI (Clemens von Pirquet for research in Allergy) and WAO (Outstanding Clinician) in the last 2 years. She has been a member of the European Academy of Allergy and Clinical Immunology (EAACI) for several years and a member of the Academy's ENT Section Committee since 2004.

Dr Scadding's research interests include rhinitis and its co-morbidities, including rhinosinusitis; aspirin hypersensitivity and sublingual immunotherapy. She is the author of over 200 publications, including the EAACI position paper "Diagnostic Tools in Rhinology" and textbooks on Investigative Rhinology and on Paediatric ENT. She also instigated the BSACI UK rhinitis guidelines, the fifth edition of which is in preparation.

Dr Scadding's travel is supported by Seqirus, a CSL company.

Basten Orator

Dr Graham Solley MBBS DABIM DABAI FACP



Dr Graham Solley was born in Toowoomba, Queensland and graduated from Medical School at the University of Queensland in 1966. He was a Resident Medical Officer (RMO) at Royal Brisbane Hospital and RMO, then Medical Registrar at Cairns Base Hospital.

Dr Solley was a Fellow in Internal Medicine (1971-1973), a Fellow in Allergic Diseases (1973-1975) and then an Associate Consultant in Internal Medicine and Allergic Diseases (1975-1976) at the Mayo Graduate School of Medicine, Rochester, Minnesota, USA.

In 1976 he gained a Fellowship of the American College of Physicians and worked as Consultant in Internal Medicine and Allergic Diseases at the Mayo Clinic (1976-1980).

From 1980 to the present Dr Solley has been a Visiting Medical Officer (VMO) in Medicine and Allergy/Immunology at the Royal Brisbane Hospital and a Consultant in Internal Medicine and Allergic Diseases in private practice at Watkins Medical Centre in Brisbane. His clinical practice has involved regular allergy clinics throughout Queensland, in Cairns, Rockhampton, Toowoomba and the Sunshine Coast.

Dr Solley is an author or co-author of over 40 published articles, primarily in the areas of:

- The late phase of the allergic immune response mediated by IgE antibodies;
- Specific testing for penicillin allergy;
- Evaluation of allergic insect sting reactions in Queensland.
- Studies of grass pollen allergy in Queensland.

At the ASCIA 2016 Conference Dr Solley will present the annual Basten Oration "Early advances in IgE antibody and eosinophil function".

Speakers and Chairs Index (A-Z)

	CFAR SYMPOSIUM SPEAKERS AND CHAIRS	ASCIA 2016 CONFERENCE SPEAKERS	ASCIA 2016 CONFERENCE CHAIRS	ASCIA 2016 NURSE AND DIETITIAN UPDATE SPEAKERS	ASCIA 2016 NURSE AND DIETITIAN UPDATE CHAIRS
Prof Abul Abbas MD, USA					
Prof Katie Allen MBBS BMedSc PhD FRACP, VIC					
A/Prof Rohan Ameratunga BHB MBChB DipABMII PhD FRACP FRCPA FRCP FRCPATH, NZ					
Prof Tony Basten AO MBBS DPhil(Oxon) FRACP FRCP FRCPA, NSW					
Ms Kathy Beck BSc GDDietNutr MHLthSc, QLD					
Ms Jan Belcher DipHlthSc Nurs, NSW					
Ms Paula Brown BSc(NutrDiet) MDA, QLD					
Prof Dianne Campbell MBBS PhD FRACP, NSW					
Dr Paul Campbell BSc(Hons) MBChB PhD FRCPA, QLD					
Ms Emily Casey BN, QLD					
A/Prof Janet Davies BSc PhD, QLD					
Ms Jillian Dimock BSc MNutrDiet, QLD					
Ms Janine English RN, QLD					
Ms Naomi Fenton RN MHLthSc MN PCAN, NSW					
Dr David Gillis MBBS(Hons) FRACP FRCPA, QLD					
Dr Paul Gray MBChB BA(Hons) MedSc MRCPCH FRACP, NSW					
Dr David Heyworth-Smith MBBS FRACP FRCPA, QLD					
Dr Patrick Hogan BSc(Med) MBBS(Hons) PhD FRACP FRCPA, QLD					
Prof Connie Katelaris MBBS PhD FRACP, NSW					
Dr Carl Kennedy BSc MBBS(Hons) FRACP FRCPA, QLD					
Dr Daman Langguth MBChB FRACP FRCPA, QLD					
Ms Liz Leins RN PgDipACN(Paed) MN, VIC					
A/Prof Richard Loh MBBS FRACP FAAAAI FACAAI, WA					

Speakers and Chairs Index (A-Z)

	CFAR SYMPOSIUM SPEAKERS AND CHAIRS	ASCIA 2016 CONFERENCE SPEAKERS	ASCIA 2016 CONFERENCE CHAIRS	ASCIA 2016 NURSE AND DIETITIAN UPDATE SPEAKERS	ASCIA 2016 NURSE AND DIETITIAN UPDATE CHAIRS
Ms Anna Majchrzak BScNutrDiet, QLD					
Prof Marcus Maurer MD, GERMANY					
Dr Karen Morwood MBBS FRACP FRCPA, QLD					
Dr Jim Muir MBBS FACD, QLD					
Dr Ray Mullins MBBS(Hons1) PhD FRACP FRCPA, ACT					
Dr Merryn Netting BSc BND AdvAPD PhD, SA					
Dr Katherine Nicholls MBBS BMedSc FRACP, VIC					
Ms Valerie Noble RN, WA					
Dr Debra Palmer PhD BND BSc, WA					
A/Prof Jane Peake MBBS DTM&H MRCP&CH FRACP, QLD					
Dr Susan Perel MBBS BSc FRACP FRCPA, QLD					
Dr Michael Perkin BSc MBBS MSc DCH MRCP MRCPCH PhD, UK					
Dr Alberto Pinzon MD PhD FRACP, QLD					
Ms Anna Richards DHlthSc NZPD, NZ					
A/Prof Sean Riminton MBChB PhD FRACP FRCPA, NSW					
Ms Ingrid Roche BSc GDDiet, WA					
Dr Sergio Rosenzweig MD PhD, USA					
Ms Maria Said RN, NSW					
Prof Hugh Sampson MD FAACAAI, USA					
Dr Glenis Scadding MD FRCP, UK					
Ms Rebecca Sertori BAppSc(Nurs) PGCFH, NSW					
A/Prof Greg Siller MBBS FACD, QLD					
Dr Anthony Smith MBBS PhD FRACP, SA					
Prof Pete Smith MBBS BMedSci PhD FRACP, QLD					

	CFAR SYMPOSIUM SPEAKERS AND CHAIRS	ASCIA 2016 CONFERENCE SPEAKERS	ASCIA 2016 CONFERENCE CHAIRS	ASCIA 2016 NURSE AND DIETITIAN UPDATE SPEAKERS	ASCIA 2016 NURSE AND DIETITIAN UPDATE CHAIRS
Dr William Smith MBBS(Hons) PhD FRACP FRCPA, SA					
Dr Graham Solley MBBS DABIM DABAI FACP, QLD					
Ms Simone Stephens DCN CNP PCHSAN, NZ					
Ms Wendy Stuart-Smith BSc DipEd MNutrDiet, NSW					
Ms Anna Sullivan BN, QLD					
Dr Anne Swain PhD BSc DNutrDiet, NSW					
Prof Mimi Tang MBBS PhD FRACP FRCPA FAAAAI, VIC					
Prof Stuart Tangye BAppSci(Hons) PhD, NSW					
Ms Leone Thiele MNursSc BA RN, VIC					
Ms Deryn Thompson SRN BN MING MBNDG MADNA, SA					
Ms Sandra Vale BScNutr Cert IV TAE, WA					
Ms Carolina Valerio BANurs BAHlthSci, NSW					
A/Prof Peter Vuillemin MBBS FRACP					
Dr Brynn Wainstein MBChB PhD FRACP, NSW					
Dr Melanie Wong MBBS(Hons) PhD FRACP FRCPA, NSW					
Dr Giovanni Zurzolo BSc(Hons) PhD, VIC					

Abstract Author Index

- Clinical Grand Rounds (CGR) 1-16
- Posters 1-79

Categories:

- T1 Food Allergy
- T2 Other Allergy
- T3 Immunodeficiency
- T4 Other Immune Diseases

ID	First Name	Last Name	Topic	Abstract Title
CGR 1	Dinusha	Chandratilleke	T2 Other Allergy	GLUCOCORTICOIDS: FROM HERO TO VILLAIN
CGR 2	Jessica	Lai	T2 Other Allergy	ALWAYS BE PREPARED
CGR 3	Helena	Jang	T2 Other Allergy	"NATURAL" THERAPY FOR ASTHMA
CGR 4	Tim	Brettig	T3 Immunodeficiency	VENO OCCLUSIVE DISEASE WITH IMMUNODEFICIENCY (VODI) TREATED WITH HAPLOIDENTICAL BONE MARROW TRANSPLANT
CGR 5	Melissa	Norman	T3 Immunodeficiency	IMMUNODEFICIENCY WITH RING CHROMOSOME 21
CGR 6	Shruti	Swamy	T3 Immunodeficiency	THE EVOLVING WORLD OF HYPOMORPHISM.
CGR 7	Brittany	Knezevic	T3 Immunodeficiency	A GAME OF HIDE AND SEEK: VARICELLA ZOSTER VASCULOPATHY IN AN ADULT WITH WISKOTT-ALDRICH SYNDROME
CGR 8	Alice	Grey T4	Other Immune Diseases	SAILING THE SEVEN C'S
CGR 9	Jocelyn	Jiang T4	Other Immune Diseases	A CASE OF IDIOPATHIC AA AMYLOIDOSIS
CGR 10	Narinder	Kaur T4	Other Immune Diseases	A RARE CASE OF ANTI-KU ANTIBODIES POSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS AND JUVENILE DERMATOMYOSITIS OVERLAP IN A PAEDIATRIC PATIENT
CGR 11	Thanh-Thao (Adriana)	Le	T4 Other Immune Diseases	A TOUCH OF GOUT
CGR 12	Jamma	Li	T4 Other Immune Diseases	SURVIVING THE GREEN NEUTROPHILIC INCLUSIONS OF IMPENDING DEATH
CGR 13	Paul	Mansfield	T4 Other Immune Diseases	AN UNUSUAL PROTEIN DEPOSITION
CGR 14	Phillippa	Pucar	T4 Other Immune Diseases	KEEPING FEVERS IN THE FAMILY
CGR 15	Mark	Taylor	T4 Other Immune Diseases	SEVERE POLYMYOSITIS WITH INTERSTITIAL LUNG DISEASE TREATED USING RITUXIMAB
CGR 16	Carlo	Yuson	T4 Other Immune Diseases	A CASE OF DEADLY SWELLING
Poster 1	Mary	Agapides	T1 Food Allergy	THE UTILITY OF SERUM-BASED TESTING IN THE DIAGNOSIS AND MONITORING OF EOSINOPHILIC OESOPHAGITIS
Poster 2	Kathy	Beck	T1 Food Allergy	SYNBIOTICS IN ATOPIC DERMATITIS
Poster 3	Jan	Belcher	T1 Food Allergy	ANXIETY IN PAEDIATRIC FOOD ALLERGY - INVOLVING CHILD LIFE THERAPISTS TO ASSIST FOOD ALLERGY MANAGEMENT

ASCIA2016

ID	First Name	Last Name	Topic	Abstract Title
Poster 4	Marie	Bodinier	T1 Food Allergy	PERINATAL EXPOSURE TO GOS/INULIN PREBIOTICS PREVENT FOOD ALLERGY BY PROMOTING TOLERANCE AND PROTECTING INTESTINE
Poster 5	Dianne	Campbell	T1 Food Allergy	ASCIA GUIDELINES FOR INFANT FEEDING AND ALLERGY PREVENTION
Poster 6	Jeannette	Comeau	T1 Food Allergy	WHY IS AUSTRALIAN POLICY STILL CAUTIOUS WITH INFLUENZA VACCINATION IN SEVERE EGG ALLERGIC CHILDREN?
Poster 7	Terri	Corderoy	T1 Food Allergy	SERUM SPECIFIC IGE LEVELS TO A – LACTALBUMIN, B – LACTOGLOBULIN AND CASEIN IN COW'S MILK ALLERGIC CHILDREN: ARE THEY SIGNIFICANT TO CLINICAL PRACTICE?
Poster 8	Chamika	De Silva	T1 Food Allergy	IMMUNOLOGICAL ANALYSIS OF NATURAL AND RECOMBINANT HEN'S EGG YOLK ALLERGEN, CHICKEN SERUM ALBUMIN
Poster 9	Preethi	Eldi	T1 Food Allergy	BIOMARKERS FOR IDENTIFICATION OF PEANUT ALLERGEN-SPECIFIC T CELLS
Poster 10	Lara	Ford	T1 Food Allergy	INCREASED ANAPHYLAXIS KNOWLEDGE AMONG TRAINERS FOLLOWING COURSE TO TEACH DELIVERY OF INTERACTIVE, SCENARIO-BASED ANAPHYLAXIS EDUCATION PROGRAM
Poster 11	Elecia	Johnston	T1 Food Allergy	IMMUNO-PCR FOR THE DIAGNOSIS OF SHELLFISH ALLERGY: THE ANALYSIS OF A NEW TECHNIQUE FOR THE SENSITIVE DETECTION OF SPECIFIC IGE ANTIBODIES
Poster 12	Thanh-Thao (Adriana)	Le	T1 Food Allergy	BASOPHIL ACTIVATION TESTING IN PEANUT AND CASHEW ALLERGY
Poster 13	Thanh-Thao (Adriana)	Le	T1 Food Allergy	FOOD AND VENOM ALLERGY REPORTS ON MEDICALERT® DEVICES
Poster 14	Tiange	Liu	T1 Food Allergy	DEVELOPMENT OF A MOUSE MODEL TO EVALUATE THE ALLERGIC CROSS-REACTIVITY TO SHELLFISH TROPOMYOSIN
Poster 15	Merryn	Netting	T1 Food Allergy	AUDIT OF FOOD ALLERGY PREVENTION ADVICE IN INFANT FEEDING EDUCATION MATERIAL WRITTEN FOR AUSTRALIAN CONSUMERS
Poster 16	Roni	Nugraha	T1 Food Allergy	IDENTIFICATION OF NOVEL OYSTER ALLERGENS USING A COMBINED TRANSCRIPTOMIC AND PROTEOMIC APPROACH FOR IMPROVED COMPONENT RESOLVED DIAGNOSIS
Poster 17	Alberto	Pinzon	T1 Food Allergy	FOOD CHALLENGE OUTCOMES FOR ULTRA-HIGH TEMPERATURE (UHT) MILK IN CHILDREN WITH COW'S MILK ALLERGY

Abstract Author Index

ID	First Name	Last Name	Topic	Abstract Title
Poster 18	Ingrid	Roche	T1 Food Allergy	ASCIA PRACTICAL INFORMATION FOR INTRODUCING SOLIDS TO INFANTS WITH KNOWN FOOD ALLERGY OR AT RISK OF DEVELOPING FOOD ALLERGY
Poster 19	Johanna	Rost	T1 Food Allergy	DISCOVERY OF 7S AND 11S GLOBULINS AS PUTATIVE ALLERGENS IN MACADAMIA NUT BY COMBINING ALLERGENOMICS AND PATIENT SERUM IGE BINDING
Poster 20	Thimo	Ruethers	T1 Food Allergy	SKIN PRICK TEST PREPARATIONS FOR SEAFOOD ALLERGY - A MOLECULAR AND IMMUNOLOGICAL ASSESSMENT
Poster 21	Sumagala	Santhakumar	T1 Food Allergy	OPEN FOOD CHALLENGES IN A REGIONAL GENERAL PAEDIATRIC SERVICE: A FIVE YEAR RETROSPECTIVE REVIEW OF WOLLONGONG HOSPITAL DATA
Poster 22	Aya	Taki	T1 Food Allergy	IS CANNED FISH REALLY SAFE?- EVALUATION OF CURRENT FOOD RECOMMENDATION USING AN ALLERGENOMIC APPROACH
Poster 23	Elizabeth	Tham	T1 Food Allergy	FOOD ALLERGY AND INFANT WEANING IN THE GUSTO COHORT
Poster 24	Carolina	Valerio	T1 Food Allergy	INFANT FEEDING PRACTICES IN INFANTS AT HIGH RISK OF ALLERGIC DISEASE
Poster 25	Christopher	Vedeler	T1 Food Allergy	PRECAUTIONARY ALLERGEN LABELLING AWARENESS IN A TERTIARY PAEDIATRIC CENTRE
Poster 26	Janet	Anderson	T2 Other Allergy	MORPHINE AND PHOLCODINE SPECIFIC IGE TESTING HAS LIMITED UTILITY IN THE DIAGNOSIS OF HYPERSENSITIVITY TO BENZYLISOQUINOLINE NEUROMUSCULAR BLOCKING AGENTS
Poster 27	Fenfen	Cai	T2 Other Allergy	ONE ANAPHYLAXIS CAUSED BY TWO STRUCTURALLY UNRELATED ANTIBIOTICS WITH EVIDENCE OF ALLERGIES TO BOTH COMPOUNDS
Poster 28	Dinusha	Chandratilleke	T2 Other Allergy	FEWER THAN 50% OF PATIENTS COMMENCING SCIT COMPLETE A 3 YEAR COURSE
Poster 29	Josh	Chatelier	T2 Other Allergy	MANAGEMENT AND FOLLOW UP OF ANAPHYLAXIS PRESENTATIONS TO THE EMERGENCY DEPARTMENT: A ONE YEAR RETROSPECTIVE AUDIT ACROSS THREE HOSPITAL SITES
Poster 30	Janet	Davies	T2 Other Allergy	THE AUSPOLLEN PARTNERSHIP: IMPLEMENTING A STANDARDIZED NATIONAL POLLEN ALERT SYSTEM FOR BETTER MANAGEMENT OF ALLERGIC RESPIRATORY HEALTH
Poster 31	Dianne	Edwards	T2 Other Allergy	PRACTICE MAKES PERFECT: THE USE OF SIMULATION IN ANAPHYLAXIS TREATMENT TO IMPROVE CLINICAL SKILLS THAT CAN LEAD TO IMPROVED PATIENT OUTCOMES

ASCIA 2016

ID	First Name	Last Name	Topic	Abstract Title
Poster 32	Dianne	Edwards	T2 Other Allergy	UTILISING NEW INITIATIVES: IMPROVING SERVICES FOR ALLERGIC HEALTH CONSUMERS BY OPTIMISING INPATIENT BOOKINGS WITHIN AN ALLERGY DAY UNIT
Poster 33	Jonas	Erjefält	T2 Other Allergy	TH2 NEUTRALIZATION AND IN VIVO ANTI-INFLAMMATORY ACTION OF PENTOSAN POLYSUPHATE SODIUM (PPS) IN AN ALLERGIC RHINITIS MODEL
Poster 34	Andrew	Fong	T2 Other Allergy	MANAGEMENT OF HOUSE DUST MITE ALLERGY IN AUSTRALIAN AND NEW ZEALAND ALLERGY PRACTICE
Poster 35	Caroline	Foreman	T2 Other Allergy	DRUG ALLERGY REPORTS ON MEDICALERT™ DEVICES
Poster 36	Abbie	Francis	T2 Other Allergy	NEUTROPHIL ACTIVATION DURING ANAPHYLAXIS
Poster 37	Lawrence	Gray	T2 Other Allergy	FAMILY HISTORY OF ALLERGIC DISEASE IS ASSOCIATED WITH ADVERSE INFANT RESPIRATORY HEALTH AND INCREASED HEALTHCARE UTILISATION: FINDINGS FROM THE BARWON INFANT STUDY
Poster 38	Sandip	Kamath	T2 Other Allergy	AN ALLERGENOMIC APPROACH FOR IDENTIFICATION OF NOVEL AIR-BORNE ALLERGENS AFFECTING CRAB-PROCESSING WORKERS DUE TO INHALATIONAL EXPOSURE
Poster 39	Joy	Lee	T2 Other Allergy	MEDICATION ADHERENCE IN A DIFFICULT ASTHMA POPULATION
Poster 40	Joy	Lee	T2 Other Allergy	PHOLCODINE-ASSOCIATED ALLERGY AND CROSS-REACTIVITY WITH NEUROMUSCULAR BLOCKING DRUGS
Poster 41	Joy	Lee	T2 Other Allergy	RISK FACTORS FOR VOCAL CORD DYSFUNCTION IN A DIFFICULT ASTHMA POPULATION
Poster 42	Richard	Loh	T2 Other Allergy	ALLERGIC RHINITIS MANAGEMENT IN AUSTRALIAN GENERAL PRACTICE
Poster 43	Michaela	Lucas	T2 Other Allergy	ASCIA CONSENSUS STATEMENT FOR ASSESSMENT OF IMMEDIATE (IgE MEDIATED) PENICILLIN ALLERGY
Poster 44	Michaela	Lucas	T2 Other Allergy	ASSESSING THE UTILITY OF THE BASOPHIL ACTIVATION TEST FOR THE DIAGNOSIS OF SUSPECTED ANAESTHETIC OR ANTIBIOTIC ALLERGY IN A WESTERN AUSTRALIAN COHORT
Poster 45	Leigh	Mackey	T2 Other Allergy	REVIEW OF ULTRA-RUSH BEE VENOM IMMUNOTHERAPY IN CHILDREN AT FLINDERS MEDICAL CENTRE
Poster 46	Odette	McNeill	T2 Other Allergy	REVIEW OF IMMUNOTHERAPY PATIENTS IN A PRIVATE CLINIC
Poster 47	Alicia	Parkes	T2 Other Allergy	300IR SUBLINGUAL TABLET OF HOUSE DUST MITE ALLERGEN EXTRACTS: EFFICACY ON RHINITIS SYMPTOMS IN SUBJECTS WITH HOUSE DUST MITE-ASSOCIATED ALLERGIC RHINITIS IN TWO PHASE III STUDIES

Abstract Author Index

ID	First Name	Last Name	Topic	Abstract Title
Poster 48	Alicia	Parkes	T2 Other Allergy	EFFICACY OF 300IR SUBLINGUAL TABLET OF HOUSE DUST MITE ALLERGEN EXTRACTS IN ADOLESCENTS WITH HOUSE DUST MITE-ASSOCIATED ALLERGIC RHINITIS
Poster 49	Alicia	Parkes	T2 Other Allergy	SAFETY OF 300IR 5-GRASS POLLEN SUBLINGUAL TABLET FOR THE TREATMENT OF GRASS POLLEN-INDUCED ALLERGIC RHINOCONJUNCTIVITIS IN ADULTS AND PEDIATRIC SUBJECTS WITH INTERMITTENT ASTHMA
Poster 50	Alicia	Parkes	T2 Other Allergy	SAFETY OF 300IR SUBLINGUAL TABLET OF HOUSE DUST MITE ALLERGEN EXTRACTS IN ADOLESCENTS WITH HOUSE DUST MITE-ASSOCIATED ALLERGIC RHINITIS
Poster 51	Alicia	Parkes	T2 Other Allergy	SAFETY OF HOUSE DUST MITE SUBLINGUAL TABLET FOR THE TREATMENT OF HOUSE DUST MITE-ASSOCIATED ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC SUBJECTS WITH INTERMITTENT ASTHMA
Poster 52	Alicia	Parkes	T2 Other Allergy	TREATMENT WITH HOUSE DUST MITE TABLETS FOR SUBLINGUAL IMMUNOTHERAPY: RELATIONSHIP BETWEEN ALLERGIC DISEASE SEVERITY AND EFFICACY IN A CONFIRMATORY STUDY
Poster 53	Mohana	Rajakulendran	T2 Other Allergy	THE IMMUNOMODULATORY ROLE OF HELMINTH PROTEIN Bm TGH-2 IN ATOPIC DISEASE: AN IN VITRO PILOT STUDY
Poster 54	Kristina	Rueter	T2 Other Allergy	INCREASE, CHARACTERISTICS, IDENTIFICATION AND MANAGEMENT OF ANAPHYLAXIS: A PERSPECTIVE OF AN AUSTRALIAN EMERGENCY DEPARTMENT
Poster 55	Kristina	Rueter	T2 Other Allergy	THE INFLUENCE OF VITAMIN D AND UV-LIGHT EXPOSURE ON THE DEVELOPING IMMUNE PHENOTYPE IN INFANCY
Poster 56	Pete	Smith	T2 Other Allergy	BURDEN OF ALLERGIC RHINITIS IN AUSTRALIA
Poster 57	Pete	Smith	T2 Other Allergy	IMPACT OF ALLERGIC RHINITIS ON HEALTH RELATED QUALITY OF LIFE: RESULTS FROM AN AUSTRALIAN SURVEY
Poster 58	Pete	Smith	T2 Other Allergy	TREATMENT PREFERENCES IN AUSTRALIAN PATIENTS WITH ALLERGIC RHINITIS: A DISCRETE CHOICE EXPERIMENT
Poster 59	Elina	Tan	T2 Other Allergy	FONDAPARINUX AS AN ALTERNATIVE IN NON-IMMEDIATE HYPERSENSITIVITY TO HEPARINS AND HEPARINOIDS
Poster 60	Sandra	Vale	T2 Other Allergy	EVIDENCE-BASED CHANGES TO ASCIA ACTION PLANS AND ANAPHYLAXIS MANAGEMENT: 2016 UPDATE

ID	First Name	Last Name	Topic	Abstract Title
Poster 61	Nicole	Van Der Burg	T2 Other Allergy	TAKING ADVANTAGE OF TOLERANCE TESTS IN THE MOUSE MODEL TO SCREEN ALTERNATIVE MICROPROJECTION PATCH DESIGNS FOR ALLERGY IMMUNOTHERAPY
Poster 62	Sherin	Vareeckal-Joseph	T2 Other Allergy	THE ROLE OF BASOPHIL ACTIVATION TEST IN THE DIAGNOSIS OF TYPE 1 HYPERSENSITIVITY REACTION MEDIATED BY BETA-LACTAM ANTIBIOTICS.
Poster 63	Lydia	Wong	T2 Other Allergy - Case	AN UNUSUAL ENTITY: CHLORPHENIRAMINE HYPERSENSITIVITY IN AN ADOLESCENT FEMALE
Poster 64	Pamela	Burton	T3 Immunodeficiency	SATISFACTION AND QUALITY OF LIFE SURVEYS ON PATIENTS RECEIVING IVIg OR SCIg, 12 MONTHS AFTER TREATMENT CHANGEOVER
Poster 65	Melissa	Norman	T3 Immunodeficiency	HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY SYNDROMES, A FIVE YEAR SINGLE CENTRE EXPERIENCE
Poster 66	Simone	Stephens	T3 Immunodeficiency	SUBCUTANEOUS IMMUNOGLOBULIN ADMINISTRATION SURVEY: SYRINGE DRIVER VERSUS RAPID PUSH
Poster 67	Simone	Stephens	T3 Immunodeficiency	SUBCUTANEOUS IMMUNOGLOBULIN IGG TROUGH LEVEL COMPARISON: SYRINGE DRIVER VERSUS RAPID PUSH
Poster 68	John	Ziegler	T3 Immunodeficiency	PATIENT PERSPECTIVES AND FOLLOW-UP ARRANGEMENTS POST HSCT FOR SEVERE COMBINED IMMUNODEFICIENCY
Poster 69	Sara	Kashef	T3 Immunodeficiency - Case	A NOVEL AICDA MUTATION IN A CASE OF AUTOSOMAL RECESSIVE HYPER-IGM SYNDROME, GROWTH HORMONE DEFICIENCY AND AUTOIMMUNITY
Poster 70	Dinusha	Chandratilleke	T4 Other Immune Diseases	IS TESTING FOR AQP4 ANTIBODIES IN CSF AND SERUM MORE SENSITIVE THAN SERUM ALONE?
Poster 71	Ghizal	Fatima	T4 Other Immune Diseases	DECIPHERING THE ROLE OF INFLAMMATORY CYTOKINES AND THEIR CORRELATION WITH CLINICAL MANIFESTATIONS IN WOMEN WITH FIBROMYALGIA SYNDROME
Poster 72	Meilyn	Hew	T4 Other Immune Diseases	SOX-1 ANTIBODIES ARE WE READY TO REPORT THEM
Poster 73	Nicholas	Kennedy	T4 Other Immune Diseases	THE IMPROVING SURVIVAL OF PATIENTS WITH SCLERODERMA OVER A 30 YEAR PERIOD
Poster 74	Fiona	Moghaddas	T4 Other Immune Diseases	AUSTRALIAN AUTOINFLAMMATORY DISEASES REGISTRY (AADRY): A NATIONAL APPROACH TO THE GENETIC AND IMMUNOLOGICAL EVALUATION OF PATIENTS WITH SUSPECTED AUTOINFLAMMATORY DISEASE

Abstract Author Index

ID	First Name	Last Name	Topic	Abstract Title
Poster 75	Fenfen	Cai	T4 Other Immune Diseases - Case	ELEVATED VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) PLAYS AN IMPORTANT ROLE IN THE DIAGNOSIS OF POEMS SYNDROME
Poster 76	Fenfen	Cai	T4 Other Immune Diseases - Case	SULPHASALAZINE-INDUCED DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) ASSOCIATED WITH NECROTISING EOSINOPHILIC MYOSITIS - A NOVEL FINDING
Poster 77	Lalita	Jindal	T4 Other Immune Diseases - Case	CAN CHEST X-RAY ABNORMALITY SUGGEST EARLY KAWASAKI DISEASE
Poster 78	Wahyu	Lestari	T4 Other Immune Diseases	A CASE OF GENERALIZED MORPHEA WITH LINEAR SCLERODERMA ON THE RIGHT LIMB
Poster 79	Mark	Taylor	T4 Other Immune Diseases - Case	RECURRENT EOSINOPHILIC PNEUMONIA TREATED USING MEPOLIZUMAB

ASCIA 2017 CONFERENCE

28th Annual Conference of the Australasian Society
of Clinical Immunology and Allergy

VIADUCT EVENTS CENTRE | AUCKLAND NEW ZEALAND | 13-15 SEPTEMBER 2017



ascia

australasian society of clinical immunology and allergy

www.allergy.org.au


ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand

Registration and abstract submission will open in April 2017

For any inquiries email education@allergy.org.au

www.ascia2017.com.au

Exhibition Floorplan



Exhibitors

ASCIA 2016

Exhibitor	Stand Number/s
Abacus-ALS	39-40
Abbott	29
Allergend	32
Allergy & Anaphylaxis Australia	33
Allergy New Zealand	34
AusEE	9
Australasian Medical and Scientific	41
Autoimmune Resource & Research Centre	11
Bayer	3-4
CSL Behring	23-26
Ego Pharmaceuticals	42
ENT Technologies	35
Grifols	21-22
GSK	7
HAE Australasia	12
IDFA	38
IDFNZ	37
Meda Pharmaceuticals	36
Mylan - Alphapharm	1-2
National Blood Authority	13
NeilMed Pharmaceuticals	31
Nestlé Nutrition / Nestlé Health Science	15-16
Novartis	14
Nutricia-Advanced Medical Nutrition	5
Nutricia-Danone	6
Octapharma	30
Seqirus	43-46
Shire Australia	17-20
Stallergenes	27-28
TAMS	10
Western Allergy	8

Sponsor and Exhibitor Directory

ABACUS ALS

www.abacus-als.com



Abacus ALS will showcase a number of new advances in allergy, asthma and autoimmunity, including new developments in allergy testing. We are also focused on standardisation across sIgE testing in laboratories throughout Australia and New Zealand. The gastrointestinal disease test menu continues to grow on the Phadia® platforms and we are pleased to provide updates on our tests performance in this important area. New tests for the EliA range include Intrinsic factor and parietal cell antibodies, anti-TSHR a new revised assay for TG and TPO and various complementary tests in the diagnosis of ANA testing.

ABBOTT NUTRITION

www.abbottnutrition.com.au



Abbott Nutrition, a division of Abbott Australasia is committed to advancing patient care by developing innovative solutions in nutritional products. Our leading-edge science is behind some of the world's most trusted names in medical nutrition, including EleCare®, which is a nutritionally complete amino acid based formula with 1/3 of fat as Medium Chain Triglycerides (MCTs), to aid fat absorption. This product has been specially formulated for infants and children who have multiple food allergies, including cow's milk protein allergy. In addition, EleCare Unflavoured and EleCare Vanilla are also indicated for the treatment of Eosinophilic Oesophagitis. EleCare® is PBS listed and is available in three variants, EleCare Unflavoured, EleCare Unflavoured with LCP and EleCare Vanilla.

ALLERGEND

www.allergend.com.au



AllergEnd has been manufacturing the highest quality dust mite resistant bedding for over 25 years. Two years ago we launched a world first innovation at ASCIA 2014, the EasyCare Mattress System. Having now been on the market for a couple of years, the response has been amazing with tremendously positive feedback.

AllergEnd strives to stay at the forefront of dust mite resistant bedding products and continues to bring the latest technology in dust mite resistant fabric to the market.

ALLERGY & ANAPHYLAXIS AUSTRALIA (A&AA)

www.allergyfacts.org.au



Allergy & Anaphylaxis Australia (A&AA) is a national, non-profit, community support organisation established in 1993 to support and assist those affected by allergy and anaphylaxis. Our aim is to improve the quality of life of those affected by allergy whilst minimising risk to their health and wellbeing. The organisation:

- Advocates for people living with allergies when communicating with government, health and teaching professionals, food industry and the broader community; and
- Strives to raise awareness of allergy in the Australian community and provide evidence-based information, resources and services to support those with allergy and those who live with the risk of anaphylaxis.

Together with ASCIA, Allergy & Anaphylaxis Australia has hosted two Allergy Summits, in August 2014 and 2015, and developed the first National Allergy Strategy for Australia, in consultation with other stakeholders. For more information on allergy and anaphylaxis see our website or call 1300 728 000.

ALLERGY NEW ZEALAND

www.allergy.org.nz



Allergy New Zealand is the national patient support organisation in New Zealand. With the support of a Medical Panel (all members of ASCIA) we work to raise awareness, provide evidence-based information and education on all allergies, and support through a national volunteer network to families with children with food allergy. Our quarterly magazine, Allergy Today, is distributed to over 5,000 health professionals. We also represent the interests of the allergic population through submissions and participation in working groups and are involved in research into the burden of food allergy in New Zealand.

AUSEE

www.ausee.org



ausEE Inc. is an Australian charity dedicated to providing support and information to anyone diagnosed with, or caring for someone with an Eosinophilic Gastrointestinal Disorder (EGID) including Eosinophilic oEsophagitis (EoE). ausEE is committed to raising public awareness and supporting the medical community for further research into eosinophilic disorders in Australia. We

have an active facebook group providing valuable support to adults with EGIDs and parents and caregivers of children diagnosed with an EGID. We offer free patient resources including children's picture books on EoE, EGID medical brochures and patient information folders. For more information, please visit our website.

AUSTRALASIAN MEDICAL AND SCIENTIFIC (AMSL)

Australia: www.amsl.com.au

New Zealand: www.nzms.co.nz



AMSL Allergy delivers leading allergy solutions to Allergists, Immunologists, dermatologists and other medical practitioners throughout Australia and in New Zealand (through NZMS).

Our portfolio includes sublingual and subcutaneous vaccines (both allergoid and native allergens), skin prick test allergens, ready to use and open type patch test systems, intradermal allergen tests for penicillin, amoxicillin and clavulanic acid, lancets and accessories.

We are proud partners of leading brands such as Immunotek, ALK, SmartPractice, Lincoln Diagnostics and Diater. We pride ourselves on our experience and expertise in the field of allergy diagnosis and immunotherapy as well as our reliable and excellent service.

AUTOIMMUNE RESOURCE & RESEARCH CENTRE (ARRC)

www.autoimmune.org.au



ARRC was established in 1989, to provide people living with systemic and organ specific autoimmune illnesses education and support services as well as access to research. ARRC services aim to reduce the impact and disease burden of illness by educating patients, carers, family and the general community on autoimmune illness, promoting healthy lifestyles and better self management choices. Programs are designed to improve overall health, quality of life and life potential whilst maintaining a balance between medical treatments, illness understanding and self-management techniques. ARRC offers a wide range of educational resource materials and education seminars for patients and health professionals.

BAYER

www.bayer.com.au

Bayer: Science For A Better Life. Bayer is an international, research-based enterprise with core competencies in the areas of



health care and agriculture. These key activities are represented by the company's business groups: Bayer HealthCare and Bayer CropScience. As an inventor company, it sets trends in research intensive areas. Bayer's products and services are developed to improve the quality of life. Bayer Australia Limited is a fully owned subsidiary of Bayer AG and has had a presence in Australia since 1925. For further information visit our website.

CENTRE FOR FOOD & ALLERGY RESEARCH (CFAR)

www.foodallergyresearch.org.au



The Centre for Food & Allergy Research (CFAR) is a collaboration of Australia's leading experts in paediatric food allergy and food-related immune disorders. CFAR was funded in 2013 as a National Health and Medical Research Council (NHMRC) Centre of Research Excellence. Our Centre includes more than 30 multi-disciplinary collaborators from 20 partner institutions. CFAR's activities aim to help curb the epidemic of childhood food allergy, decrease the public health burden and ensure that children with food allergy are provided with the best care and treatment. Our collective world-class research efforts provide evidence to optimise food allergy management and find novel treatments. CFAR collaborates with governments, health bodies and the community to: communicate our research findings; support the development of evidence-based public health policies and clinical practice guidelines; and, promote consistency in the diagnosis and management of allergic conditions. CFAR also plays a pivotal role in training the next generation of paediatric food allergy researchers.

CSL BEHRING

www.cslbehring.com.au

CSL Behring

With a proud Australian heritage, and driven by our commitment to improve the lives of people with a range of serious and often rare medical conditions, CSL Behring is a global leader in research, development and supply of plasma products, and an emerging supplier of recombinant therapies.

As the chosen national plasma fractionator of Australia and New Zealand, CSL Behring manufactures an extensive range of quality plasma products for each country from plasma collected from its own respective donors, with indications in some immunodeficiencies and autoimmune conditions, bleeding disorders, urgent reversal of warfarin anticoagulation, and in trauma, shock and burns.

In Australia we supply additional global CSL Behring products manufactured from plasma collected in the US

Sponsor and Exhibitor Directory

and Europe including HIZENTRA® (SCIg) and PRIMIGEN® (IVIg) which are used in a range of immunodeficiency and immunomodulatory settings and supplied under current NBA tender arrangements, and BERINERT® which is indicated for treatment of hereditary angioedema attacks.

EGO PHARMACEUTICALS

www.egopharm.com

From our inception as a family business in 1953, Ego has grown to become a world leader by producing a comprehensive skincare range made in Australia. Our reputation is built on consistently manufacturing effective, high-quality skincare products such as market leaders 'QV', 'Sunsense', 'Pinetarsol', 'DermAid' and 'Moov'. The QV range of gentle moisturisers and cleansers has been scientifically formulated for those who suffer from dry or sensitive skin conditions. The entire QV range is free from colour, fragrance, propylene glycol, lanolin and its derivatives, making it ideal for the most sensitive skin types.

Ego continues to innovate and invest in research and development for a sustainable future in the skin care category. Ego products are sold via pharmacies, to help people restore and maintain skin health.



ENT TECHNOLOGIES

www.enttech.com.au

ENT Technologies Pty Ltd is a wholly Australian owned business which specialises in the formulation, development and delivery of novel pharmaceutical preparations for the management of both acute and chronic pathologies of both nasal and sinus cavities. ENT Technologies has pioneered the introduction of FLO – a range of sterile, preservative-free multi-dose nasal sprays in Australia. It was also first to formulate sinus irrigations with Ringers solution (FLO Sinus Care) rather than just salt and sodium bicarbonate and to further develop this preservative free technology into a very low ionic strength irrigation solution which would not interfere with innate immunity in the paranasal sinuses. ENT Technologies welcomes discussion with surgeons and clinical immunologists who have unique requirements for their patients. If we can help, we will.



GRIFOLS

www.grifols.com

GRIFOLS

Grifols is a global healthcare company with more than a 75-year legacy of improving people's health and well-being through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products. Health commitment drives our activity organised into three divisions: Bioscience, Diagnostic, and Hospital, which develop, produce and market innovative products to medical professionals in more than 100 countries worldwide.

GSK

www.gsk.com.au



GlaxoSmithKline (GSK) is a global research-based pharmaceutical and healthcare company with a mission to improve the quality of human life by enabling people to do more, feel better and live longer. In Australia we have improved people's wellbeing by delivering the highest quality medicines, vaccines and over-the-counter healthcare products since 1886. We provide about 1700 skilled jobs across the country, working with researchers and doctors to discover new ways of treating and preventing disease. In 2012 we invested \$54 million in local research and development, and supplied \$521 million to Australia's pharmaceutical and medicinal exports.

HAE AUSTRALASIA

www.haeaustralasia.org.au

HAE Australasia Ltd is a not for profit organisation, founded by HAE patients and caregivers and is dedicated to improving the quality of life of those living with Hereditary Angioedema (HAE) in Australia and New Zealand.

HAE Australasia provides education to patients, carers and health care providers, raises the awareness of HAE in the medical and general communities and assists research organisations with their studies into causes, prevention and treatment of HAE. HAE Australasia is also looking at ways to make treatment and medications more accessible for patients across Australia and New Zealand.

IDFA

www.idfa.org.au



Immune Deficiencies Foundation of Australia (IDFA) is the patient organisation for people affected by Primary Immune Deficiencies in Australia. IDFA provides education, information, advocacy, communication and support to

members. IDFA is governed by a Board of Directors which includes two leading Australian Immunologists (Paediatric and Adult). IDFA is a member of IPOPI (International Patient Organisation for Primary Immunodeficiencies) and has representation on the IPOPI Board. IDFA welcomes membership from Immunologists and other Health Professionals. For further information, email christine.jeffery@idfa.org.au, call 0409 945 114 or visit our website.

IDFNZ

www.idfnz.org.nz



Immune Deficiencies Foundation of New Zealand (IDFNZ) is a registered charity which has served patients of all ages with diagnosed Primary Immune Deficiency (PID) disorders since 1989. IDFNZ offers individual patient support, education, advocacy and information. IDFNZ also sponsors medical and scientific research, and promotes awareness of PID to the general public and health professionals including visiting speaker and awareness programmes. IDFNZ is governed by a volunteer Board which includes representatives from our medical advisory panel, comprising of leading medical professionals specialising in PID disorders. IDFNZ is a foundation member of the International Patient Organisation for Primary Immune Deficiencies (IPOPI).

MEDA

www.meda.com.au



MEDA is a global pharmaceutical company, recently acquired by Mylan, with an exciting portfolio of products in dermatology, respiratory/allergy and OTC. Our company culture embraces innovation and creativity. We celebrate new ideas and getting things done. We are committed to quality products and happy customers. To find out more about MEDA products, visit our website.

MYLAN - ALPHAPHARM

www.mylan.com.au



There are 7 Billion Reasons why we do what we do. At Mylan, We have a vision of "Better health for a better world". We are committed to providing access to quality healthcare for the world's 7 billion people, one person at a time. We call this aspiration 7B:1. Anaphylaxis, a life-threatening allergic reaction, is a significant public health problem. When anaphylaxis occurs, every minute matters and immediate access to adrenaline-epinephrine and emergency medical

care is crucial. We advocate for increased anaphylaxis awareness, preparedness and access to treatment, because even one anaphylactic episode without access to adrenaline (epinephrine) is one too many.

Mylan's EpiPen® [(adrenaline) epinephrine auto-injector] is the number one prescribed adrenaline auto-injector in Australia. Mylan supplies EpiPen® to Australians via the PBS, with two pens available on each prescription.

NATIONAL ASTHMA COUNCIL

www.nationalasthma.org.au



The National Asthma Council Australia is the national authority for asthma knowledge, working to improve the health, social and economic impacts of asthma. In setting the standards for asthma care, the Council works with a network of leading experts to write the national treatment guidelines for asthma, provides education and support to health professionals, promotes best-practice care to people with asthma and their families, and advocates for the whole asthma community.

NATIONAL BLOOD AUTHORITY

www.blood.gov.au



The National Blood Authority (NBA) is responsible for providing an adequate, safe, secure and affordable supply of blood and blood products and promotes safe, high quality management and use of these products.

Visit the NBA website for up to date information, tools and material on patient blood management, product and inventory management, wastage reduction, immunoglobulin products and much more.

NEILMED PHARMACEUTICALS

www.neilmed.com



NeilMed Pharmaceuticals manufacture allergy and sinus relief products that are highly effective for rhino sinusitis, allergies, and most beneficial for post FESS patients. NeilMed's Sinus Rinse Kit is a soothing saline nasal irrigation system with 60 packets of preservative free, isotonic, pH balanced mixture, irrigation bottle and custom designed cap. NeilMed's NasaFlo is a free flowing gravity method to nasal irrigation. NeilMed's NasoGel is a soothing saline gel for prolonged miniaturization of dry nasal passages. NeilMed's NasaMist is a buffered, preservative free nasal spray, isotonic and hypertonic available. NasaDrops, Ampoules with Aspirators, Saline ampoules for stuffy, congested or dry noses for babies, children and adults. Tel: 1 300 652 148

Sponsor and Exhibitor Directory

NESTLÉ

www.nestlehealthscience.com.au

Nestlé is the world's leading Nutrition, Health and Wellness company. Through integrating scientific and research expertise, Nestlé Nutrition aims to pioneer the development and application of evolving science to help infants and children develop to their full potential plus create a new role for nutrition in disease prevention and management. Together Nestlé Health Science and Nestlé Infant Nutrition offer high quality nutrition products for the crucial first years of life and nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages.



www.nestlenutrition-institute.org

The Nestlé Nutrition Institute (NNI) is not-for-profit and shares the latest science based information and education with health care professionals to foster "Science for Better Nutrition", and contribute to the enhancement of the quality of people's lives all over the world.

NOVARTIS

www.novartis.com.au

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas.



We have more than 60 years' history in Australia and employ around 800 associates across our three divisions. We believe continued R&D is essential to innovation and in Australia we invest around 20M annually in local clinical trials.

Our mission is to discover new ways to improve and extend people's lives. We are committed to patients, associates, healthcare partners and society at large to improve access to healthcare and essential medicines as we aspire to become a trusted leader in changing the practice of medicine.

To find out more about Novartis in Australia visit our website.

NUTRICIA ADVANCED MEDICAL NUTRITION

www.neocatevillage.com.au



DANONE NUTRICIA EARLY LIFE NUTRITION

www.danonenutriciaprofessional.com.au



Nutricia leads the way with more than 40 years of experience in providing a comprehensive portfolio for Advanced Allergy Management. Our products are scientifically researched for the protection and management of cows' milk protein allergy and multiple food protein allergies. We look forward to discussing with you how Nutricia's expertise and comprehensive allergy portfolio can assist you. By offering an unmatched superior product, range, evidence and support, Nutricia can help you make a difference to the lives of the infants, children and mothers you care for at every step of their allergy journey.

OCTAPHARMA

www.octapharma.com.au



Octapharma specialises in the development and production of human proteins derived from plasma and recombinant technologies. As a global supplier we remain committed to the Australian marketplace for the long term. Using cutting-edge purification and viral inactivation techniques we live by our mission of "for the safe and optimal use of human proteins." We provide life-saving therapies to our patients in the treatment of multifarious diseases in Haematology, Immunotherapy, Intensive Care and Emergency Medicine. Octapharma operates and manufactures products to the highest standards of quality and safety required by physicians, patients and regulatory authorities globally. For more information visit our website.

SEQIRUS

www.seqirus.com.au



Seqirus, a CSL company, is a leading provider of essential vaccines, pharmaceuticals and diagnostic reagents. As the second largest influenza business in the world, Seqirus operates Australia's only onshore manufacturing facility for seasonal and pandemic influenza vaccine, and produces medicines of national significance including antivenoms and the Q fever vaccine. Seqirus first entered the allergy market in 2005 with EpiPen® (epinephrine injection) as CSL Biotherapies. We are proud to return to the allergy space joining the fight against allergic disease.

As a CSL company, we're proud of our heritage, and as we celebrate our centenary, we remember that it all started here in Australia.

We are Seqirus, and we're just getting started.

SHIRE AUSTRALIA

www.shireaustralia.com.au



Newly combined with Baxalta, Shire is now the leading global biotechnology company focused on serving people affected by rare diseases and highly specialised conditions. These diseases are often misunderstood, undiagnosed and life-threatening.

Our 22,000 employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

At Shire, we are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care.

Working together, the possibilities for our patients, healthcare partners and employees are unprecedented, with significant growth potential for our shareholders.

STALLERGENES GREER

www.stallergenes.com STALLERGENES  GREER

Stallergenes Greer Life beyond allergy combines over 100 years of allergy expertise of Greer in the USA with Stallergenes' history of innovation in allergen immunotherapy from France. With a strong commitment to research and development, Stallergenes Greer dedicates close to 20% of its turnover each year to the development of innovative and evidence-based treatments. Locally, Stallergenes Greer is dedicated to its long term partnership with the Australasian allergist community to address the unmet need of patients suffering from moderate to severe allergic respiratory disease. Our efforts are oriented to this cause and are seen through consistent support and grants we provide, along with delivering the only TGA and Medsafe registered allergen immunotherapy treatments in Australia and New Zealand.

THE AUSTRALASIAN MASTOCYTOSIS SOCIETY (TAMS)

www.mastocytosis.com.au



TAMS was formed in 2011 and is working to;

- Provide a network of support for patients living with Mastocytosis or a Mast Cell Activation Disorder (MCAD) and their carers
- Connect patients to medical practitioners and specialists with knowledge of Mastocytosis and MCAD
- Link together with similar associations worldwide to collectively gather research data, share resources and knowledge in the hope of greater understanding, treatment practices, medications and improved overall health outcomes for those living with Mastocytosis or MCAD.

WESTERN ALLERGY

www.westernallergy.com.au

www.allerssharp.com



Western Allergy Australia supplies immunology products and services in Australia. We provide allergists and immunologists with premium quality products, accompanied by unparalleled service. We are an Australian company, and are exclusively committed to serving the needs of local healthcare professionals and their patients.

Western Allergy Australia utilises the technological skills and scientific experience Western Allergy has earned in Canada over the past four decades. Western Allergy has successfully treated tens of thousands of patients with SLIT alone, created over 250 unique SCIT dosage paradigms, and currently provides products and services to almost 400 allergy specialists. Established in 1972, Western Allergy Services has solidified itself as the premier supplier of allergy diagnostics, allergy immunotherapy and atopic treatment in Canada. This reputation is the result of utilising the highest quality raw materials, state of the art manufacturing facilities, and an uncompromising dedication to client & patient satisfaction. These premium products and renowned services are now available to Australian healthcare professionals and their patients for the very first time.

EPIPEN® EPIPEN® Jr

[Adrenaline (Epinephrine)] Auto-Injectors 0.3/0.15mg

20+
YEARS¹

NO.1 PRESCRIBED
ADRENALINE (EPINEPHRINE)
AUTO-INJECTOR²

HOLIDAYS HAPPEN.
Be prepared.



- The leading treatment for anaphylaxis in Australia, saving lives for over 20 years^{1,2}
- Globally trusted by patients with anaphylaxis and severe allergies³



Visit the Mylan stand to collect your tag
Stand #1 – just like EpiPen®²


PBS Information: Authority Required. Refer to PBS Schedule for full authority information.

BEFORE PRESCRIBING, PLEASE REVIEW APPROVED PRODUCT INFORMATION
AVAILABLE ON REQUEST FROM ALPHAPHARM.

MINIMUM PRODUCT INFORMATION EpiPen® Adrenaline Auto-Injector 0.3mg / 0.3mL EpiPen® Jr. Adrenaline Auto-Injector 0.15 mg / 0.3mL. The following are not a complete listing: **Indication:** For the emergency treatment of anaphylaxis [acute severe allergic reaction] due to insect stings or bites, foods, drugs or other allergens. **Contraindications: Contraindications are relative, as this product is intended for use in life-threatening emergencies.** Certain arrhythmias, cerebral arteriosclerosis, vasopressor drug contraindication, shock (except anaphylactic shock), certain types of general anaesthesia. **Precautions:** Sulfite allergy, intravenous administration, ventricular fibrillation, prefibrillatory rhythm, tachycardia, myocardial infarction, cardiovascular disease, organic heart disease, cardiac dilation, cerebral arteriosclerosis, prostatic hypertrophy, elderly, individuals with diabetes, hypertension, narrow angle glaucoma, hyperthyroidism, organic brain damage, psychoneurosis, phenothiazine-induced circulatory collapse, Parkinsonism. Avoid injection into hands, feet, ears, nose, buttocks, genitalia. Use in Pregnancy: Pregnancy Category A. Excreted in breast milk. Use with caution when maternal blood pressure is in excess of 130/80. **Interactions:** CNS medicines, alpha and beta adrenergic blockers, some general anaesthetics, hypoglycaemic agents. **Adverse Effects:** Anxiety, restlessness, tachycardia, respiratory difficulty, tremor, weakness, dizziness, headache, dyspnoea, cold extremities, pallor, sweating, nausea, vomiting, sleeplessness, hallucinations, flushing of face and skin. Psychomotor agitation, disorientation, impaired memory, potentially fatal ventricular arrhythmias, severe hypertension which may lead to cerebral haemorrhage and pulmonary oedema. Angina may occur in patients with CAD. **Dosage:** Single intramuscular injection into anterolateral aspect of thigh, repeat as directed if symptoms recur or have not subsided. Adults > 30kg: EpiPen® Auto-Injector [0.3mg adrenaline] Children 15–30kg: EpiPen® Jr. Auto-Injector [0.15mg adrenaline]. The prescribing physician may choose to prescribe more or less than this amount; please refer to relevant guidelines.

References: **1.** Australian Register of Therapeutic Goods (ARTG) EpiPen® and EpiPen® Jr registration, 20/08/1993. Available at <https://www.ebs.tga.gov.au/> accessed August 2016. **2.** Pharmaceutical Benefits Schedule Item Reports. Available at medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp (items 3408J, 8697R, 3409K, 3698T), accessed August 2016. **3.** Ram FSF. *J Allergy Ther* 2012;3(116):1–3. EpiPen® is a registered trademark of Mylan, Inc. EpiPen® and EpiPen® Jr. are distributed in Australia by Alphapharm Pty. Limited. ABN 93 002 359 739, Level 1, 30 The Bond, 30–34 Hickson Road, Millers Point, NSW, 2000. Customer Service: **1800 274 276**, www.mylan.com.au inCeptiv ALP0770 August 2016

 Mylan®



More than 4 million Australians suffer from allergic rhinitis and/or allergic asthma.¹ Studies suggest almost half of those sufferers are sensitised to house dust mites.^{2,3}

Poorly controlled upper and lower respiratory symptoms can severely impact patients' lives, affecting their sleep, daily routines and quality of life.^{1,4}

*It shouldn't have to be a living nightmare.
Target the cause, not just the symptoms.⁵*

**Please visit us at booth 43-46,
and go to www.allergymatters.com.au
for more information on house dust mite allergy**

Seqirus™: Proud to be Diamond sponsors of the 2016 ASCIA conference

References: 1. AIHW. Allergic rhinitis ('hay fever') in Australia. November 2011. 2. Chivato T et al. *J Investig Allergol Clin Immunol* 2012; 22: 168-79. 3. Bauchau V, Durham S.R. *Eur Respir J* 2004; 24: 758-64. 4. Valovirta E, Pawankar R. *BMC Pulm Med* 2006; 6(Suppl 1): S3. 5. Klimek L et al. *Expert Rev Clin Immunol* 2016; 12: 369-77. Seqirus™ is a trademark of Seqirus UK Limited or its affiliates. ABN 66 120 398 067. Seqirus (Australia) Pty Ltd, 63 Poplar Road, Parkville, Victoria 3052. www.seqirus.com.au. Date of Preparation July 2016. SEQ/ARAA/0716/0077. AM6636

Seqirus™
A CSL Company

AVAILABLE
OTC

FOR FORMULA-FED INFANTS



COW'S MILK PROTEIN ALLERGY?

THINK NEW **novalac** ALLERGY

In Australia and New Zealand, approximately **1 in 50** babies have confirmed cow's milk protein allergy (CMPA).¹



- ✓ Reduces allergy symptoms associated with CMPA including regurgitation, eczema, diarrhoea and constipation.^{2,3}
- ✓ Tolerated by over 90% of babies with a demonstrated CMPA.^{2,3}
- ✓ Has a mild, pleasant taste, unlike some extensively hydrolysed or amino acid-based formula.²⁻⁴
- ✓ Nutritionally complete, contains Omega 3 and Omega 6, and suitable for use from birth.

The first and only 100% rice protein-based infant formula available in Australia



SPECIALIST IN INFANT FEEDING CONDITIONS



Breast milk is best for babies. Professional advice should be followed before using an infant formula. Introducing partial bottle feeding could negatively affect breastfeeding. Good maternal nutrition is preferred for breastfeeding and reversing a decision not to breastfeed may be difficult. Infant formula should be used as directed. Proper use of an infant formula is important to the health of the infant. Social and financial implications should be considered when selecting a method of feeding.

References: 1. Australasian Society of Clinical Immunology and Allergy. Cow's milk (dairy) allergy. 2016. 2. Vandenplas Y *et al.* *Eur J Paediatr.* 2014; 173(9):1209-16. 3. Vandenplas Y *et al.* *Arch Dis Child.* 2014; 99:933-6. 4. Pedrosa M *et al.* *J Investig Allergol Clin Immunol.* 2006; 16:351-6. CH-00751. August 2016. S&H 08/16 BAYN00009

CARING FOR PEOPLE

Grifols has a long history in pioneering the tools and techniques currently used in the collection and purification of human plasma for therapeutic use.

**Sponsored by:
Grifols Australia Pty Ltd**

Unit 5/80 Fairbank Road,
Clayton South VIC 3169
Australia

Tel: +61 3 9535 9333
Fax: +61 3 9535 9300
Email: Australia_info@grifols.com

Date of preparation: July 2016
GRIAE0050

BECAUSE EVERYONE
SHOULD FEEL WELCOME
AT HOME



Once-daily immunotherapy tablet¹

Established formulation^{2,3}

Targets the cause, not just the symptoms⁴

Sustained post-treatment efficacy⁵

Indicated for patients >12 years²

Optimal dose for efficacy and safety⁶

Actair[®]

Mixture of American (*D. farinae*) and European (*D. pteronyssinus*) house dust mite allergen extracts

The new therapeutic option
for house dust mite allergy¹

PBS Information – This product is not listed on the PBS

Please review full product information before prescribing. Full product information is available from www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?openagent&id=cp-2016-pi-01700-1&d=2016050216114622483

ACTAIR Initiation Treatment Sublingual Tablets 100 IR & 300 IR Mixture of American (*D. farinae*) and European (*D. pteronyssinus*) House dust mite allergen extracts ACTAIR Continuation Treatment Sublingual Tablets 300 IR Mixture of American (*D. farinae*) and European (*D. pteronyssinus*) House dust mite allergen extracts Indications Treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults and adolescents over 12 years diagnosed with house dust mite allergy. Contraindications Hypersensitivity to any of the excipients; severe, uncontrolled or unstable asthma; immune deficiency diseases or active forms of auto-immune disorder; malignant diseases; oral inflammations Precautions Oral surgery, evaluate patients with asthma, tricyclic antidepressants, mono amine oxidase inhibitors, rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, Eosinophilic esophagitis For all precautions refer to full PI Adverse effects: Oedema mouth, oral pruritus, ear pruritus, stomatitis, abdominal pain, tongue oedema, lip oedema, oral discomfort, diarrhoea, nausea, paraesthesia oral, dyspepsia, throat irritation, oropharyngeal discomfort, cough, pharyngeal oedema, dyspnoea, nasopharyngitis, gastroenteritis, bronchitis, acute tonsillitis, dermatitis atopic, headache, ear pain, glossitis, oral mucosal blistering, hypoaesthesia oral, gastritis, cheilitis, dry throat, conjunctivitis, pruritus, urticarial For all adverse effects refer to full PI. Dosage & Administration It is recommended that the first tablet of ACTAIR is taken under medical supervision and that the patient is monitored for 30 minutes. On first day, one 100 IR tablet. Tablet must be placed under the tongue until complete disintegration and then swallowed. On second day, two 100 IR tablets must be placed under the tongue simultaneously and swallowed after complete disintegration. On third day and onwards, one 300 IR tablet placed under the tongue until complete disintegration and then swallowed. It is recommended that the tablets be taken during the day in an empty mouth. Refer to full PI for dosage details. Date of first inclusion in the ARTG TGA approval 15/04/2016

References: 1. Therapeutic Goods Administration. Search of the Australian Register of Therapeutic Goods (ARTG) "house dust mite immunotherapy" at www.tga.gov.au (date searched 22/08/16). 2. ACTAIR Approved Product Information. 3. Bousquet J *et al. Allergy* 1999;54:249–260. 4. ASCIA. The economic impact of allergic disease in Australia: not to be sneezed at. 2007. Available at: www.allergy.org.au/images/stories/pospapers/2007_economic_impact_allergies_report_13nov.pdf (accessed August 2016). 5. Bergmann KC *et al. J Allergy Clin Immunol* 2014;133:1608–14. 6. Demoly P *et al. Clin Transl Allergy* 2015;5:44. Stallergenes Australia Pty Ltd t/a Stallergenes Greer, ABN 17 151 366 540, Suite 2408, 4 Daydream St, Warriewood, NSW 2102. Phone 1800 824 166. Email: office@stallergenes.com.au. Distributed in Australia for Stallergenes Australia Pty Ltd by EBOS Group Pty Ltd Clayton Vic. Stallergenes and ACTAIR are registered trademarks of Stallergenes SAS. STG12186. August 2016. OSTA0078.

STALLERGENES  GREER

New insights into the management of HAE

A Shire educational dinner meeting

Wednesday 14 September 2016 | 6.30pm – 9.30pm

Gold Coast Convention Centre - Central Room A
2684 Gold Coast Highway Broadbeach, Queensland



Guest speaker

Professor Marcus Maurer

Professor of Dermatology and Allergy,
Director of Research, Department of Dermatology and Allergy
Associate Director of the Allergie-Centrum-Charité
Charité-Universitätsmedizin (University Hospital) Berlin, Germany

Chairperson

Professor Constance Katelaris

Head of Unit, Professor Immunology & Allergy
Western Sydney University and Campbelltown Hospital
Chair, ASCIA HAE Working Party NSW, Australia

Shire Australia invites you to an educational dinner meeting with leading international dermatology and allergy expert **Professor Marcus Maurer**, who will share **new insights into the management of Hereditary Angioedema (HAE) and highlight advances in the assessment of quality of life measures for patients.** This meeting is being held in association with the Australasian Society of Clinical Immunology and Allergy (ASCIA) annual conference. This invitation is open to all conference delegates and will be held at the same venue as the conference.

Meeting Program

Time	Session
6.30pm	Registration
7.00pm	Welcome address
7.10pm	Entree
7.30pm	“New insights into the management of HAE”
8.15pm	Question time
8.30pm	Main course
8.50pm	Additional question time and discussion
9.30pm	Meeting close

Registration is required. Please visit the Shire trade display to register
(On right hand side of exhibition hall entrance)

Personal information collected from you by Shire when you respond to this invitation will only be used for the communication about and other organisational activities related to this event. Your personal information will be treated in accordance with applicable laws and in accordance with Shire policies. For more information you can check Shire's privacy notice at www.shireaustralia.com.au or contact the Privacy Officer by e-mail at privacyconnect@shire.com or call (02) 8019 4400. In accordance with Medicines Australia Code of Conduct for the Australian prescription medicines industry, any costs (eg, travel or meals) incurred by a partner spouse, guest or family member travelling with a healthcare professional, may not be paid for or subsidised by the company.

As committed as ever, prepared like never before

With a proud Australian heritage, CSL Behring is a global leader in developing innovative plasma products. As the national plasma fractionator for Australia and for New Zealand, together with our extensive global supply and R&D network, we are firmly committed and prepared like never before to serve Australia's and New Zealand's growing needs for plasma products.

CSL's Melbourne operations in 1920's

CSL Behring's Melbourne operations in 2015



A proud Australian heritage, today
a global leader in plasma products¹



Australia's own plasma products, manufactured by CSL Behring in Broadmeadows Victoria from Australia's plasma, collected by the Australian Red Cross Blood Service



Additional CSL Behring plasma products imported for supply in Australia

One more reason why HIZENTRA[®] is a SCIg therapy that conforms to life*

*Statistically significant (p-value <0.05) improvement in satisfaction with medication convenience and life quality index score relating to patient therapy setting, treatment interference and therapy related problems in PID patients, compared to previous IVIg treatment.¹⁻⁴



Introducing flexible dosing options: from daily to every 2 weeks¹

SCIg = Subcutaneous Immunoglobulin
PID = Primary Immunodeficiency
IVIg = Intravenous Immunoglobulin


**PBS Information: This product is not listed on the PBS
Please refer to the National Blood Authority for details**

Please review Product Information before prescribing. The Product Information can be accessed at www.cslbehring.com.au/au-pi

Minimum Product Information HIZENTRA[®] (Normal Immunoglobulin (human) 20% (20g/100mL), subcutaneous injection. **Indications:** Replacement therapy in primary immunodeficiency disease and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. **Contraindications:** Severe systemic allergic reaction to active substance or excipients. Hyperproliferative disease. **Precautions: SUBCUTANEOUS use ONLY. DO NOT administer Intravenously (IV),** shock can develop if accidentally administered IV. Infusion must be stopped immediately if severe hypersensitivity reaction occurs. Monitor during and for the first hour after first infusion patients a) that are naive to human normal Ig, or b) that have switched from an alternative Ig product, or c) with long interval since previous infusion. All other patients monitor during and at least 20 minutes post infusion. Those with anti-IgA antibodies, in whom treatment with subcutaneous IgG remains only option, switch to Hizentra only under close medical supervision. Cases of aseptic meningitis syndrome, embolic and thrombotic events have been reported with immunoglobulin treatment. **Pregnancy and lactation:** Hizentra given with caution, immunoglobulin crosses placenta and present in breast milk; limited clinical study data, clinical experience suggests no harmful effects. **Pathogen safety:** donor screening and dedicated viral inactivation/removal manufacturing procedures used, however, possibility of viral transmission cannot be totally excluded. **Interactions:** May affect the response to live attenuated vaccines. May interfere with some serological tests. For all precautions, etc., review approved product information (PI). **Adverse Effects:** infusion site reactions and headache. For all adverse events review approved PI. **Dosage & Administration:** Dose needs to be individualised for the patient. Loading dose: at least 0.2 to 0.5 g/kg (1.0 to 2.5 mL/kg), which may need to be divided over several days. Maintenance doses: administered at repeated intervals to reach a cumulative monthly dose of around 0.4 to 0.8 g/kg (2.0 to 4.0 mL/kg). Administered subcutaneously into sites such as abdomen, thigh, upper arm, and lateral hip. Large doses (>25 mL) recommended to be administered at multiple sites (sites at least 5 cm apart). Initial infusion rate should not exceed 15 mL/hour/site. If well-tolerated, rate can be gradually increased to 25 mL/hour/site. Maximum of 50mL/hour for all simultaneous infusion sites combined. Contains no preservative, use immediately after opening, discard unused portion. Do not use if cloudy or contains particulate matter. Based on HIZENTRA[®] Approved Product Information 25 May 2016 (V 6.00).

References: 1. Hizentra Approved Product Information. 2. Jolles S, Sleasman J. *Adv Ther* 2011; 28(7):521-33. 3. Anderson D, Caspi A. *P&T* 2010; 35 (8): SECTION 2. 4. Quevedo TG *et al.* Health-related quality of life of patients with primary immunodeficiency switching from intravenous IgG to a new 20% subcutaneous IgG. [abstract no. F39]. *Clin Immunol* 2010; 135 Suppl: S87. Poster presented at the 10th Annual Meeting of the Federation of Clinical Immunology Societies; 2010 Jun 24-27; Boston (MA). For customer service enquiries for plasma-derived therapies within Australia phone: 1800 063 892; from outside Australia phone: +61 3 9246 5231. For medical information enquiries for plasma-derived therapies phone: 1800 642 865. CSL Behring (Australia) Pty Ltd. 189-209 Camp Rd, Broadmeadows VIC 3047, Australia. ABN 48 160 734 761. Hizentra is a registered trademark of CSL Behring AG. HIZ16-07-0047. Date prepared August 2016. HIZ0047.

27 years of ASCIA Annual Conferences 1990-2016



1990	Melbourne VIC (Hilton on the Park, April 29 - May 1)
1991	Perth, WA (Burswood Hotel, December 1-3)
1992	Cairns, QLD (Hilton Hotel, September 13-15)
1993	Sydney, NSW (Darling Harbour, April 29 – May 1)
1994	Canberra, ACT (Lakeside Hotel, December 2-5)
1995	Sydney, NSW (Regent Hotel, October 30-November 3) held with TPAIS
1996	Adelaide, SA (Hyatt Hotel, December 5-7)
1997	Wellington, NZ (Convention Centre, April 5-8) held with TSANZ
1998	Brisbane, QLD (Sheraton Hotel, August 28-30)
1999	Uluru, NT (Ayers Rock Resort, September 24-27)
2000	Sydney, NSW (Convention Centre, October 15-20) (held as part of the 17th World Allergy Congress)
2001	Perth, WA (Sheraton Hotel, September 28-30)
2002	Adelaide, SA (Hilton Hotel, September 27-29)
2003	Melbourne, VIC (Sheraton Southgate Hotel, September 10-12)
2004	Gold Coast, QLD (Marriott Hotel, September 8-10)
2005	Queenstown, NZ (Millennium Hotel, August 31 - September 2)
2006	Sydney, NSW (Manly Pacific Hotel, September 7-9)
2007	Fremantle, WA (Esplanade Hotel, November 14-16)
2008	Melbourne, VIC (Park Hyatt Hotel, November 12-14)
2009	Adelaide, SA (Adelaide Convention Centre, September 16-18)
2010	Gold Coast, QLD (Gold Coast Convention and Exhibition Centre, September 1-4)
2011	Sydney, NSW (Sydney Convention & Exhibition Centre, Darling Harbour, September 6-10)
2012	Wellington, NZ (Wellington Town Hall, September 5-8)
2013	Perth, WA (Perth Convention and Exhibition Centre, September 10-14)
2014	Melbourne, VIC (Melbourne Convention Centre, September 10-13)
2015	Adelaide, SA (Adelaide Convention Centre, September 8-12)
2016	Gold Coast, QLD (Gold Coast Convention and Exhibition Centre, September 13-17)

**ascia**

australasian society of clinical immunology and allergy

www.allergy.org.au